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RESEARCH ORGANIZATIONS AND MAJOR DISCOVERIES 
INTRODUCTION 
This paper is a small part of a much larger historical and cross-national research 
agenda in which the author has been engaged for more than a decade. The agenda has 
confronted two major problems: (1) How does the institutional environment in which actors 
are embedded constrain their behavior (Hollingsworth, 1986; Hollingsworth, Hage, and 
Hanneman, 1990; Campbell, Hollingsworth, and Lindberg, 1991; Hollingsworth, Schmitter, 
and Streeck, 1994; Hollingsworth and Boyer, 1997; Hollingsworth, 2000), and (2) How do 
the structure and culture of organizations facilitate or hamper their innovativeness 
(Hollingsworth and Hollingsworth, 2000a, 2000b; Hage and Hollingsworth, 2000; 
Hollingsworth, Hollingsworth, and Hage, 2002 forthcoming; Hollingsworth, Müller, and 
Hollingsworth, 2002 forthcoming). 
The paper addresses the problem of how the structure and culture of research 
organizations influence the creation of fundamental new knowledge. More specifically, the 
paper is part of a research project which is concerned with the question of why research 
organizations varied in their capacity to make major breakthroughs in biomedical science in 
the twentieth century. The perspectives that have been useful in shaping this project have 
come from diverse sources — the literatures on national systems of innovation, on 
organizational innovation, on evolutionary economics, on organizational capabilities, and 
literatures in the history and sociology of science. The ideas in these literatures have been 
refined and extended through many dozen historical case studies of major discoveries, 
which my colleagues and I have conducted in approximately 200 research organizations in 
twentieth-century Britain, France, Germany, and the United States (Hollingsworth, 
Hollingsworth, and Hage, 2002 forthcoming; also see unpublished sources noted at the end 
of this paper). 
The theoretical framework of the paper is used to analyze the structure and culture 
of the one research organization which had more major breakthroughs in biomedical 
science than any other in the twentieth century: the relatively small Rockefeller University 
in New York City. Hopefully, this case study will shed light on the kinds of organizational 
strategies, structure and culture which facilitate the creation of fundamental new knowledge 
in very hybrid fields of science. 
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CONCEPTS, DATA, AND METHODS 
THE CONCEPT “MAJOR DISCOVERY” 
 
For purposes of this paper, and related research (Hollingsworth, Hollingsworth, and 
Hage, 2002 forthcoming), a major breakthrough in biomedical science is defined as a 
finding or process, often preceded by numerous “small” advances, which leads to a new 
way of thinking about one or more important problems (Ben-David, 1960: 828; Merton, 
1961, 1973; Rosenberg, 1994: 15). This new way of thinking is highly useful for numerous 
scientists in diverse fields of science in addressing problems. This is very different from the 
rare paradigm shifts Thomas Kuhn analyzed in his classic The Structure of Scientific 
Revolutions (1972). Major breakthroughs about particular problems in biomedical science 
occur within the paradigms about which Kuhn was writing. Historically, a major 
breakthrough in biomedical science was a radical or new idea, the development of a new 
methodology, or a new instrument or invention. It has usually not occurred all at once, but 
has rather involved a process of investigation taking place over a substantial period of time 
and a great deal of tacit and/or local knowledge (Polanyi, 1966; Latour, 1987). 
To implement the concept “major discovery,” I rely heavily on the scientific 
community, drawing on criteria the scientific community has created to recognize major 
discoveries. Using a diverse set of strategies to operationalize the definition, I include 
discoveries which led to either the winning or near winning of a major prize. Though I rely 
heavily on discoveries associated with major prizes as a strategy for defining major 
discoveries, I am very careful to avoid a restriction to any single prize. For a discussion of 
the prizes (and near winning of prizes) used as indicators of major discoveries, see Note 
One below.1 
                                                 
1 The indicators of major discoveries are: (1) discoveries resulting in Copley Medal awarded since 1901 by 
the Royal Society of London, insofar as the award was for basic biomedical research, (2) discoveries resulting 
in a Nobel Prize in Physiology or Medicine since the first award in 1901, (3) discoveries resulting in a Nobel 
Prize in Chemistry, also since the first award in 1901, if the research had high relevance to biomedical science 
(this includes discoveries in biochemistry as well as an occasional breakthrough in several other areas of 
chemistry), (4) discoveries resulting in 10 nominations in any three years prior to 1940 for a Nobel Prize in 
Physiology or Medicine, or in Chemistry if the research had high relevance to biomedical science. The 
rationale is that this number of nominations suggests that broad support existed in the scientific community to 
the effect that the research represented a major scientific breakthrough even if it did not result in a Nobel 
Prize. Since the number of people who could make nominations for Nobel Prizes in the first half of the 
twentieth century was quite restricted by present day standards, this criterion of “10 and 3” represents broad 
recognition among nominators during those years), (5) Every year, the Royal Swedish Academy of Sciences 
and the Karolinska Institute each appointed a committee to study major discoveries and to propose Nobel 
Prize winners (in Chemistry, and in Physiology or Medicine, respectively). These two committees have made 
shortlists of discoveries considered to be “prize-worthy,” and some of the discoveries were recognized for 
Nobel Prizes. I include in my population the discoveries on the shortlists through 1940 which were not 
recognized for Nobel prizes. My colleagues and I have had access to the Nobel Archives for the Physiology or 
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The emphasis on diverse fields of science is critical for my definition of a major 
breakthrough. Most biomedical research is highly incremental and specialized and is 
reported to highly specialized audiences. And, while I do not suggest that this kind of 
research is trivial or unimportant, its impact is more confined to specialized researchers, 
whereas the research which is described herein as major breakthroughs is widely 
recognized and highly appreciated in diverse fields of science. In short, major discoveries 
are types of knowledge absorbed by scientists across a number of different specialties, and 
major breakthroughs have tended to reflect a high degree of scientific diversity, as distinct 
from being highly specialized and narrow research. 
Having identified a major discovery, my colleagues and I have then determined 
with a large number of case studies when and in what research organization(s), 
department(s), and lab(s) the discovery occurred. In some instances, the research 
organization did not have departments. 
One goal of the case studies has been to identify organizations associated with 
major discoveries, and to allocate them “credit” for the major discoveries with which they 
were associated. In some cases, scientists made their major discoveries by conducting 
research first in one organization, before moving on to another with the same line of 
research. All the organizations in which scientists did work that was directly associated 
with major discoveries have been credited with the discovery. 
The research takes note that all scientists who were engaged in making major 
discoveries were not always recognized by prize committees. However, this is a study 
about major discoveries and the properties of the research organizations where they 
occurred. Thus, the omission of “unrecognized” individuals by prize committees does not 
significantly bias our results. With one or two exceptions, unrecognized scientists were 
engaged in research at the same organizations as recognized scientists (Gura, 2001: 564; 
also see Howlett, 1998: 625–626). Our method of conducting in-depth studies of the 
organizations, departments, and/or labs where a major discovery occurred obviously 
permits us to identify those scientists who were involved but did not receive recognition by 
a prize committee. 
This research is not a history of scientific ideas or a study of the creativity of 
individual scientists, although it acknowledges that discoveries were made by individuals 
                                                                                                                                                     
Medicine Prize at the Karolinska Institute and to the Archives at the Royal Swedish Academy of Sciences in 
Stockholm for this period, but for reasons of confidentiality, access to these archives is not permitted for the 
past 50 years. To capture the variety of major scientific discoveries during the later period, I also use several 
other criteria. I included (6) discoveries resulting in the Arthur and Mary Lasker Prize for basic biomedical 
science, (7) discoveries resulting in the Louisa Gross Horwitz Prize in basic biomedical science, and (8) 
discoveries in biomedical science resulting in the Crafoord Prize, awarded by the Royal Swedish Academy of 
Sciences. For purposes of this paper, I have included the above forms of recognition through the fall, 2000. 
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and that creativity occurs at the level of individuals (Hollingsworth, 2001). The concern of 
this paper is with the research laboratory and/or department and organization associated 
with the making of major discoveries. Major discoveries do not occur at random in 
organizations, labs, and departments. Rather, there are regularities in the characteristics of 
organizations and labs and/or departments where they occur, and these are the issues 
addressed in the broader research project as well as in this particular paper. 
 
 
DATA AND METHODS 
 
Once we have identified when and where a breakthrough occurred, we have then 
turned to a much more difficult and labor-intensive task—the determination of the 
properties of the organization and the laboratory where the discovery occurred. Informed 
both by our case studies and the theoretical literature on organizations, we structure our 
analyses around the following basic concepts: (1) organizational autonomy, (2) 
organizational flexibility/inertia, (3) scientific diversity, (4) differentiation of the 
organization and/or departments into subunits, (5) communication and integration across 
diverse fields of science, (6) leadership that has the capacity to develop strategies for 
integrating scientific diversity, and (7) hierarchical and bureaucratic coordination (i.e., 
standardization of rules and procedures). Because the key methodology is one of 
conducting case studies of the organizational context in which major discoveries occurred, 
it is possible to identify the key organizational concepts associated with major discoveries 
and to identify the causal ordering.  
As a result of our case studies, we have identified the following organizational 
characteristics as most important in facilitating the making of major discoveries. 
(1) Organizational autonomy. The capacity of an organization to make scientific 
appointments, engage in new lines of research, and organize new laboratories or 
departments according to the criteria which it develops independently of external 
disciplinary norms and governing authorities (for a discussion of this issue, see 
Hollingsworth, 2000). 
(2) Organizational flexibility. The ability of an organization to shift rapidly to new 
and different research areas. 
(3) Moderate scientific diversity. The existence of a variety of biomedical 
disciplines and subspecialties. For scientific diversity to exert maximal beneficial effect, 
there must be depth (e.g., individuals highly competent in the following task areas: 
theoretician, methodologist, scientist highly conversant with literature in various fields, 
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scientist highly competent in the latest instrumentation in diverse fields). The greater the 
proportion of the scientific staff who internalize scientific diversity, the greater the 
likelihood that scientific breakthroughs will occur. For additional details on diversity, see 
below. 
(4) Communication and social integration among the scientific community. The 
bringing together of different cognitive perspectives through frequent and intense 
interaction in types of activities such as (a) joint publications, (b) journal clubs, (c) sharing 
meals and leisure time activities. 
(5) Leadership capacity to understand the direction in which scientific research 
is moving and to develop strategies for integrating scientific diversity. Outstanding 
leaders have been able to engage in tasks which are both task oriented and socio-emotional 
in nature. At both the organizational and the laboratory level, they have been individuals 
with (a) strategic vision for integrating diverse areas and for providing focused research, (b) 
ability to secure funding for these activities, (c) ability to recruit sufficiently diverse 
personnel for research groups to be constantly aware of significant and “doable” problems, 
(d) ability to provide rigorous criticism in a nurturing environment, (e) capacity to 
orchestrate a diverse group of scientists in the present and at the same time to orient a 
scientific staff toward future directions. 
While the diversity of perspectives creates problems of communication because of 
the cognitive distances among individuals, in organizations having recurrent major 
discoveries leadership plays a critical role in providing the means to overcome these 
difficulties. Our data demonstrate that one important function of the emotionally supportive 
leader is to encourage people to take intellectual risks and to participate in an open give-
and-take climate of communication. Under these circumstances, hidden assumptions are 
often expressed, implicit knowledge may become codified, and radical ways of thinking 
about problems are more likely to slowly emerge. 
(6) Recruitment. Organizations which have major discoveries time and time again 
tend to be ones where there is a moderately high level of scientific diversity which is well 
integrated. Organizations which have this kind of routine tend to recruit for permanent 
positions scientists who internalize moderately high levels of diversity at the time of their 
permanent appointments. These scientists tend to have very broad research interests. 
If an organization is to make radical breakthroughs across time, it needs to be not 
only flexible but also ambidextrous in its internal operations—both taking the necessary 
incremental steps so that strategy, structure, leadership, and personnel are linked to one 
another in a fairly harmonious fashion on a day–to-day basis AND taking radical or 
revolutionary steps to look beyond the present so that the organization can quickly adapt to 
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significant changes in the environment. The organization which can make major 
discoveries time and time again is one that can do both of these things (Hollingsworth, 
Hollingsworth, and Hage, 2000 forthcoming; Hage and Hollingsworth, 2000; Tushman and 
Romanelli, 1985; Tushman and O’Reilly, 1996; Romanelli and Tushman, 1994; Porter, 
1991). 
Science is very dynamic, constantly changing. Research areas that have been lively 
forums for research can quickly subside. Changes in technology and the development of 
new instrumentation often have the unintended consequences of permitting scientists to 
pose new questions and provide new solutions to older problems. As well, research 
organizations that make major discoveries time and time again must have the flexibility to 
make careful adjustment to fluctuations in governmental policies and sources of funding, 
and to volatility in the national and international economy. Coping successfully with 
constantly changing environments requires organizations to modify their strategies and 
their structures, encountering risks as they unbalance their existing systems. Such 
adjustments are necessary if research organizations are to do more than simply engage in 
incremental research addressed to highly specialized audiences. 
An organization accustomed to the delicate balancing of strategy, structure, 
leadership, and personnel cannot lightly alter one of these components, lest its operating 
system be endangered. Within organizations, change in organizational strategy, structure, 
and leadership styles is often unwelcome, even resisted, inasmuch as it requires moving 
away from norms, habits, and conventions which had previously been effective. 
Organizations develop myths and cultural heroes, not easily set aside, and the development 
of new strategies and structures can be very stressful. Once such shifts are made, they can 
be perpetuated only if they are institutionalized, so that the mix of strategy, structure, 
leadership, and personnel enters a new balance (and eventually a new period of 
equilibrium). 
With most research organizations, it is only after there has been substantial decline 
in organizational performance that there is a realization that fundamentally new strategy, 
structure, personnel, and leadership are needed if the organization is to have the potential to 
remain at the frontiers of science. An organization which can anticipate the need to make 
radical changes at the same time that it is vigorously continuing its productive present is an 
unusual organization. Rockefeller Institute/University—the subject of this paper—was 
highly successful in making numerous major breakthroughs over the last century precisely 
because of its ability to carry out this dual activity: to maintain its established practices at 
high levels of performance, and to look beyond the near future to make radical changes in 
its practices. 
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The achievements of the Rockefeller have been very uncharacteristic of research 
organizations across the globe. Most organizations tend to experience a great deal of 
inertia, generally failing to make radical changes in their structure, strategy, leadership, and 
personnel as environments change. Even organizations that have performed well have a 
tendency to congeal in self-congratulation, idealizing their own practices to such an extent 
that they do not adequately modify themselves in response to environmental change. 
Leaders in research organizations are confronted with a dilemma. Over the short 
term they must strive to have congruence between the strategy, structure, and personnel of 
an organization. But over the long term, the leadership must be sufficiently able to reorient 
the strategy, structure, and personnel of the organization if it is to remain at the frontiers of 
science, the boundaries of which are always changing. In other words, the high performing 
organization is subjected to contradictory pressures—it must strive to keep strategy, 
structure, personnel, and leadership aligned, but in order to adapt to the fast pace of change 
in the global world of science, the leadership must at the same time constantly alter 
strategies, structure, and personnel. 
In our research, we have also studied a control group of laboratories and research 
organizations (Hollingsworth, Hollingsworth, and Hage, 2002 forthcoming). These are 
research organizations which enjoy high reputations as places which conduct excellent 
science, but they have rarely had scientists who have made major breakthroughs in 
biomedical science. In these organizations, we have also done in-depth studies of the 
laboratories headed by distinguished scientists (e.g., scientists who are members of national 
academies but have not made a major breakthrough). Our research has revealed that the 
following organizational properties have hampered the making of major discoveries: 
(1) Differentiation. Differentiation is concerned with sharp boundaries among 
scientific areas, that is, with formal, structural properties of units, such as (a) the number of 
biomedical departments and other kinds of units, (b) delegation of recruitment exclusively 
to the department or other subunit, (c) responsibility for extramural funding solely at 
department or other subunit level. Organizations which are highly differentiated into 
departments which, in turn, are fragmented into subspecialties tend to recruit scientists who 
are highly specialized and somewhat narrow in their research interests. 
(2) Hierarchical authority and bureaucratic coordination. This involves (a) 
centralized budget controls, (b) centralized decision-making about research programs, (c) 
centralized decision-making about number of personnel, (d) standardization of 
rules/procedures. 
(3) Hyperdiversity. The presence of scientific diversity to such a deleterious degree 
that there cannot be effective communication among actors across diverse fields of science. 
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Significantly, these properties have been more pronounced in very large research 
organizations. Larger organizations have tended to be highly differentiated and 
bureaucratic, and thus rarely to have major breakthroughs in biomedical science. 
Figure One below portrays one of the most important processes relating to 
discovery in biomedical research organizations. It applies to research organizations having 
few or no major discoveries as well as to those having major discoveries time and time 
again. In organizations where there is little scientific diversity, there is unlikely to be 
radical or highly innovative thinking about existing problems. If there is little scientific 
diversity, there is little potential for novelty. Most scientific research is incremental in 
nature and tends to take place in organizational environments (laboratories) where 
researchers operate in a relatively narrow framework. In contrast, major breakthroughs, 
even when based on numerous experiments of an incremental nature, tend to take place in 
organizational environments in which there is intense and frequent communication across 
moderately high levels of scientific diversity (Hage and Hollingsworth, 2000; 
Hollingsworth and Hollingsworth, 2000; Hollingsworth, Hollingsworth, and Hage, 2002 
forthcoming). Having scientists concentrated in the same mind-set is inhibiting to the 
making of major discoveries. What is needed for major breakthroughs is to have scientists 
bring together varied complementary skills—with intense and frequent communication—in 
order to see problems from new perspectives. 
Our data have also revealed that the organizations with numerous major discoveries 
have tended to be sites where scientists from diverse backgrounds have been able to engage 
in intense and frequent communication with each other (see Figure One). Simply expressed, 
when scientific diversity remains unintegrated, the stimulation of varying perspectives is 
not realized. Therefore, the issue of how to integrate diverse ways of thinking and to 
facilitate the communication of tacit knowledge (i.e., to codify it) becomes a critical one in 
research organizations if they are to have major breakthroughs in biomedical science time 
and time again. This kind of communication is advanced by the social integration of 
scientific staffs. 
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FIGURE ONE 
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In our research there have been only six organizations worldwide which have had 
large numbers of major breakthroughs in biomedical science in the twentieth century, so 
many breakthroughs that we refer to them as “national champions.” These are the Institut 
Pasteur in France, the University of Cambridge in Britain, and in the United States, 
California Institute of Technology, the College of Arts and Sciences at Harvard University 
(as distinct from the Harvard Medical School), the Johns Hopkins University School of 
Medicine, and Rockefeller University. However, Rockefeller University led all other 
organizations in the number of major breakthroughs in biomedical science across the 
twentieth century. What follows is a case study of Rockefeller University, designed to shed 
some light on how it achieved and retained this level of excellence. 
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INSTITUTIONALIZING AND MAINTAINING A CULTURE OF EXCELLENCE 
 
Understandably, leaders and scientists of the Rockefeller did not always correctly 
understand and respond to the changes in the global world of science. They did not always 
anticipate the major institutional and scientific patterns of change in America, nor did the 
organization consistently have the same level of excellence in its flow of ongoing work. 
Even so, why would Rockefeller University—a small organization in New York City not 
known by millions of Americans—have had more major discoveries in biomedical science 
throughout the twentieth century than such renowned organizations as Harvard, Yale, the 
University of California at Berkeley, and Stanford University in the United States; 
Cambridge and Oxford Universities in Britain; and the Pasteur Institute in Paris? And, in 
the biomedical sciences, why would it have had more major breakthroughs in biomedical 
science than all the Kaiser Wilhelm and Max Planck Institutes combined (see Appendix 
One for Rockefeller scientists who made major breakthroughs in biomedical science across 
the last century)? The key to this problem requires some comprehension of the 
development of a culture of excellence at Rockefeller shortly after its foundation. 
To understand the origins of the Rockefeller organization, we need to recognize that 
in the latter part of the nineteenth century, the United States lagged far behind the frontiers 
of biomedical science as they existed in Europe—especially in Germany. Throughout the 
nineteenth century, the United States did not have high standards in biomedical science and 
did not provide high quality training for young scientists and physicians. Most medical 
schools had few if any laboratories, they were rarely affiliated with hospitals or 
universities, and their capital outlays were generally quite small (Flexner, 1910). Of course, 
some schools were better than others, and a few Americans made contributions to medical 
knowledge, but overall even the best medical schools and centers for research in the United 
States were inadequate. Among the best were those of the University of Pennsylvania, 
Harvard, Yale, the University of Michigan, and Columbia. Though by 1900 they were 
progressing in basic science research, the training and research at each of these schools fell 
far short of the best medical advances of the time. Since Germany had become the center 
for scientific medicine in the late nineteenth century, more than 15,000 Americans went 
there between 1870 and 1914 to study the medical sciences. In the history of American 
biomedical science, few things are of greater importance than the traveling of this 
generation of Americans to Germany, especially in the 1870s and 1880s. They attempted to 
bring back what they found, and it was these German institutions and ideas that ultimately 
revolutionized science and clinical medicine in the United States (Flexner and Flexner, 
1941; Eliot, 1923: 28, 35; Ludmerer, 1986; Hollingsworth, 1986: 82–125). 
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All of this must be set in the context of the major institutional changes taking place 
in the United States during the second half of the nineteenth century. There was a 
transformation in the American economy, which produced unprecedented wealth in 
America. John D. Rockefeller, Sr., one of the most important entrepreneurs of American 
capitalism, believed that “the power to make money is a gift from God ... to be developed 
and used to the best of our ability for the good of mankind. I believe my duty is to make 
money and still more money and to use the money I make for the good of my fellow man 
according to the dictates of my conscience” (Collier and Horowitz, 1976: 48). To assist in 
his philanthropic activities, Rockefeller chose Frederick T. Gates, a Baptist minister, who 
quickly immersed himself in understanding Rockefeller’s business and philanthropic 
affairs. Gates had a keen interest in medical matters. In an effort to learn more about the 
best medical practices of the day, he read the famous The Principles and Practice of 
Medicine by William Osler, one of the great medical men of the day but a “therapeutic 
nihilist” who believed that physicians knew very little about the specific cures of most 
diseases. Osler’s pessimism about the capacity of physicians to cure illness led Gates to 
conclude that there was an urgent need to improve the state of biomedical knowledge. 
Very much aware of the Institut Pasteur in Paris and Robert Koch’s institute in 
Berlin, in 1897 Gates submitted a proposal to Rockefeller in which he argued that although 
various departments of natural sciences had been generously endowed in American 
universities, medicine, because of the commercial orientation of medical schools, had not 
been well supported. As a result, medical research was in a poor condition in America, 
usually conducted by practitioners who could at best steal a short time from their private 
practices. He argued that medicine could hardly hope to become a science until research 
was properly endowed and dedicated scientists were permitted to have uninterrupted study 
and investigation, completely independent of clinical practice. To achieve these ends, he 
proposed the establishment of a research institute. With Rockefeller’s son, John D. 
Rockefeller, Jr., a new graduate of Brown University, Gates developed a wonderful 
working relationship in managing the Rockefeller philanthropic affairs in general, and more 
specifically, in the development of a biomedical research institute (Gates, 1977: 165, 179–
188; Brown, 1979). 
As both men quickly realized that they needed the advice of people with a rich 
knowledge of medical science, they sought out a distinguished group. Rockefeller Jr. 
consulted with his family physician, Dr. Emmett Holt, a renowned pediatrician and author 
of the leading textbook on pediatrics; William H. Welch, the Dean of the Johns Hopkins 
Medical School; Christian Herter, a well known scientific investigator who had established 
his own private laboratory in New York City for his research in biochemistry, 
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pharmacology, and bacteriology; Hermann M. Biggs, head of the Division of Bacteriology 
of the New York City Department of Health; T. Mitchell Prudden, Professor of Pathology 
at the Columbia University College of Physicians and Surgeons (who had known Welch 
since their student days in Germany in the 1870s); and Theobald Smith of the Harvard 
Medical School, the leading American bacteriologist of the day and a former student of 
Welch’s. Welch suggested the addition of his former student at Johns Hopkins, Simon 
Flexner, then Professor of Pathology at the University of Pennsylvania. Eventually these 
people became members of the Board of Directors of the Rockefeller Institute (Rous, 1949: 
417; Corner, 1965: 35; Clark, 1959b, Zinsser, 1937). 
Each had training in pathology, and each believed that the best strategy at the time 
for attacking disease was to use the tools of bacteriology. Each also thought that it was only 
a matter of time before physiology and chemistry would have to be integrated with 
bacteriology in order to advance knowledge of diseases. Despite common elements in their 
scientific backgrounds, the group represented diversity in biomedical science, which in the 
long term was to prove valuable to the Rockefeller Institute. Herter had extensive 
experience in research and in clinical practice; Holt in hospital clinical practice; Biggs and 
Smith had backgrounds in public laboratories, and Smith, Welch, Prudden, and Flexner 
were researchers in university medical schools. From the very beginning there was very 
high trust and camaraderie among these men, and this is extremely important in 
understanding the early success of the Institute. 
One of the most important contributors to the success of the Rockefeller Institute 
was William H. Welch, who had already been instrumental in establishing Johns Hopkins 
as the premier medical school in North America. The more Welch reflected on the idea of 
an institute, the more he was impressed by its potential, so when he was pressed by 
Rockefeller Jr., Gates, and the small group of scientific advisors, he agreed to serve as 
president of the new institute’s board, a position he held for thirty-two years. The choice of 
Welch as President of the Board is indicative of the capacity of the Rockefellers to recruit 
excellent people to implement their programs. Some have argued that Welch had more 
influence in developing the biomedical sciences in the United States than anyone else in 
American history. In addition to serving for more than three decades as President of the 
Board of the Rockefeller Institute, he served as President of the American Association for 
the Advancement of Science and was the first President of Pathologists and Bacteriologists, 
President of the American Medical Association, President of the Association of American 
Physicians, Member of the Board of Trustees of the Hooper Foundation for Medical 
Research at the University of California, President of the National Academy of Sciences, 
one of the key individuals in establishing the National Research Council, Member of the 
 16 
RESEARCH ORGANIZATIONS AND MAJOR DISCOVERIES 
Board of Trustees of the Carnegie Institution in Washington from 1906 to 1934, and 
Chairman of its Executive Committee from 1909 to 1916. As a key figure in these 
organizations and as President of the National Academy of Sciences, Welch had better 
contact with the elite in all fields of American science than anyone else. In his own field of 
pathology, virtually no important university post in America was filled without his approval 
in the first third of the twentieth century (Fleming, 1954: 131–137; Flexner and Flexner, 
1941). The Rockefellers could not have made a better choice than Welch to steer the initial 
board of the Rockefeller Institute. He had an excellent understanding of the direction in 
which biomedical science was moving, high visibility and legitimacy in American science, 
and outstanding judgment about the type of scientists and the specific scientists whom the 
Institute should recruit. 
One critical decision was what kind of organization the Rockefeller Institute should 
be. Because of their academic backgrounds, Welch, Prudden, Flexner, and the other 
scientific advisors tended to think the new organization should be linked to an existing 
university. However, the Rockefellers and Gates were insistent that there be no formal link 
with a university. The idea of the Institute, as conceived by the Rockefellers and Gates, 
laymen who had become sensitive to the shortcomings of medical knowledge, was that 
biomedical knowledge could not be substantially advanced until an organization existed 
with proper endowment, and with qualified scientists with adequate salaries, independent of 
private medical practice and university teaching, and devoting all its time to research 
(Flexner, 1930: 458; Flexner and Flexner, 1941; Gates, 1977). 
 
 
THE DIRECTORSHIP OF SIMON FLEXNER 
 
Welch proposed Simon Flexner as the first director. Here too, a better choice could 
hardly have been made. Flexner had many of the traits of other leaders who have served 
various Rockefeller family philanthropies during the past century—of humble origin, not 
having attended the nation’s most distinguished academic institutions, but ultimately a 
leader in the world of scholarship. Flexner, the fourth of five children, was born to Jewish 
parents in Louisville, Kentucky, and grew up in semi-poverty after his father died 
prematurely. Shortly after receiving his medical degree at an undistinguished medical 
school in Louisville, he went to Johns Hopkins in the early 1890s—though not as a regular 
medical student—where he became associated with Welch. Quickly, the breadth of his 
education increased. With the backing of Welch, Flexner also went to Europe and studied 
in some of its great laboratories. He worked in the laboratory of one of America’s most 
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distinguished biomedical scientists, Jacques Loeb at Woods Hole. Slowly, Flexner was 
integrating medical and biological science, so that by the time he became the director of the 
Institute he had demonstrated that he was a creative and productive scientist, capable of 
absorbing and integrating new and complex ideas, that he had the capacity to develop and 
implement new research programs, and that he could operate on many fronts at once 
(Blumenthal, 1991). 
Appointed as the first director in 1901, Simon Flexner left an indelible mark on the 
Institute. As a result of his efforts and achievements, the expectation developed among the 
Trustees of the Rockefeller that it should be headed by an individual who had a strategic 
vision for integrating scientific diversity, who could create an organizational environment 
which blended criticism and nurturing, who had the capacity to recruit personnel alert to 
significant problems and able to solve them, and who was able to secure funds. Over the 
past century, not all subsequent heads of Rockefeller have lived up to the leadership 
standards which Flexner epitomized, but these are the ideals by which successive leaders 
have been evaluated. 
Whereas the Koch Institute in Berlin and the Institut Pasteur in Paris were founded 
around great scientists and their research, the Rockefeller Institute was a new kind of 
research organization which from the beginning emphasized diversity in the biomedical 
sciences. Instead of focusing on one specific area of science, the Institute pursued research 
in multiple areas of the biomedical sciences. Biomedical research was changing very 
rapidly by the time the Rockefeller Institute was established. Because bacteriology had 
become closely linked with pathology, and both fields were becoming more closely related 
to discoveries in organic and physical chemistry, as well as in physics, a broad conception 
of biomedical science was the guiding philosophy of the Institute from the beginning. 
The recruiting of an initial staff proved to be very difficult. Most senior professors 
in leading American medical schools and universities viewed the Rockefeller Institute as a 
high-risk “upstart,” and they were unwilling to leave the security of their permanent 
positions for it. Most young people, hoping for careers at established universities, also 
viewed the Institute with some suspicion. Moreover, many medical practitioners perceived 
the scientific agenda of the Institute as an assault on their legitimacy. Indeed, the dominant 
tone of the medical profession of New York City was quite hostile to basic biomedical 
research (Rous, 1949: 417). 
For some years, there had been vicious attacks in the American press by Henry 
Demarest Lloyd, Ida Tarbell, and others against “Rockefeller money” and the Standard Oil 
Trust, and at the time of planning for the Institute, much of the nation’s press was hostile to 
Rockefeller. Young scientists were frequently warned to steer clear of the Institute. Peyton 
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Rous, a future Nobel laureate from the Institute, and Jacques Loeb, one of the most 
important scientists in its history, had initial reservations about going there because they 
feared they might not have freedom to conduct their research (Pauly, 1987: 134–136; Rous, 
1949: 418). 
Flexner thought it necessary to recruit not only young people but also at least a few 
experienced scientists. But since senior American professors were unwilling to accept 
positions there, the initial members of the staff were a “motley group” (Rous, 1949: 418). 
The resulting senior staff had outstanding ability, but no involvement with established 
American universities and academic disciplines, which proved to be a blessing in disguise. 
For the most part, the choices for initial appointments were opportunistic and 
personalistic in nature. Flexner placed considerable emphasis on the recruiting of scientists 
whose origins were in different cultural and scientific areas (e.g., Alexis Carrell from 
France; Karl Landsteiner from Austria; Hideyo Noguchi from Japan; Phoebus Levene and 
Samuel Meltzer from Russia; Jacques Loeb, Leonor Michaelis, and Max Bergmann from 
Germany). Several were of Jewish origin in an era of strong anti-Semitism. Almost every 
one of these scientists internalized cultural diversity in his own cognitive makeup, which 
increased the potential for crossing scientific disciplines. Feeling an affinity for others who 
crossed academic discipline boundaries, the early-appointed scientists established and 
reinforced a culture based on broad, interdisciplinary approaches to scientific problems. 
From the beginning, the Institute did not organize the production of knowledge 
around academic disciplines, the usual practice in major universities. In organizations in 
which academic disciplines were dominant for organizing and coordinating the production 
of knowledge, there was a tendency to recruit specialists in disciplines, scientists who by 
definition internalized less scientific diversity (and, often, less cultural diversity). The 
distinctive Rockefeller recruitment of scientists socialized in several cultures, subsystems, 
disciplines, or working environments meant a staff with more potential to acquire new 
styles of thought and scientific competence. From the outset, Rockefeller was a place where 
scientists were willing to participate in multiple scientific worlds simultaneously, fostering 
the cross-fertilization of ideas and the opportunity for communication across diverse fields 
of research. These conditions facilitated the development of the hybridization of ideas 
which over time leads to scientific creativity, sudden insights, and the opening of novel 
pathways to difficult problems. 
As a research organization, the Institute had several distinct advantages over most 
universities. Most teaching organizations attempt to present an entire field of knowledge to 
their students and find it awkward to neglect certain sub-fields. They tend to recruit people 
less because of their research excellence than because of the necessity to cover a particular 
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area of knowledge. Unlike a university, a research institute has no obligation to cover an 
entire field of knowledge, and it can be very opportunistic in terms of the fields on which 
research is undertaken. It can neglect or pursue fields, can recruit scientists solely on the 
basis of their ability to attack selected problems, and has the flexibility to move into new 
areas with considerable rapidity. Moreover, the Rockefeller Institute had the luxury of 
being able to recruit scientists of excellence even if they had limited ability to speak 
English or could not teach (Flexner, 1930). 
Generous financial endowment by the Rockefellers created excellent working 
conditions for scientific research. A number of other institutes founded at about the same 
time were also very well endowed: the Phipps Institute in Philadelphia, established by the 
steel magnate Henry Phipps; the Memorial Institute for Infectious Diseases in Chicago, 
funded by Harold McCormick, a son-in-law of John D. Rockefeller; and the Carnegie 
Institution in Washington, endowed by Andrew Carnegie. One could list more. However, 
the history of the Rockefeller Institute, viewed in a comparative perspective, suggests that 
while financial resources are necessary for outstanding research, they are less important 
than having the right strategy, structure, personnel, and leadership. An organization must be 
able to do excellent work on a continuing, day-to-day basis, but at the same time must be 
willing to reorient itself continually so that it anticipates scientific change. The Rockefeller 
Institute, with its laboratory structure, was ambidextrous enough to be able to adapt quickly 
to its environment, to move in new directions at the same time as it was carrying on more 
established lines of research. If a research organization is to have major discoveries time 
and time again, one of its most important resources is the quality of its leadership, a 
variable to which most organizational sociologists give scant attention. Over the years, the 
Rockefeller has had several directors/presidents who were capable of interacting in a 
meaningful way with its scientists and who personally knew the leading biomedical 
scientists of the world. Of the eight directors or presidents since the founding of the 
Rockefeller Institute, six made major discoveries in biomedical science and the two who 
made no major biomedical discoveries (Detlev Bronk and Fred Seitz) were distinguished 
scientists who had been President of the National Academy of Sciences. Four of the eight 
were Nobel laureates in physiology or medicine.2 
Originally, a single Board of Directors designed and implemented plans for the 
development of the new institute, but in 1910 Welch, who had been President of the Board 
                                                 
2 Simon Flexner served as Director until 1935 and Herbert Gasser from 1935 until 1953. After 1953, the 
title Director was dropped in favor of President. Detlev Bronk served as President 1953–1968, Fred Seitz 
1968–1978, Joshua Lederberg 1978–1990, David Baltimore 1990–1991, Torsten Wiesel 1991–1998, and 
Arnold Levene 1998 to the present. 
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of Directors, became President of the Board of Scientific Directors, and due in part to the 
prestige he lent the Institute, some of America’s leading biomedical scientists subsequently 
agreed to serve on the Board. Over time Board members included future Nobel laureates 
Vincent du Vigneaud, Herbert Gasser, and George Whipple, alongside three other scientists 
who made major breakthroughs in biomedical science: Walter B. Cannon of Harvard, Ross 
Harrison of Yale, and Theobald Smith of Harvard (mentioned above). In addition, Detlev 
W. Bronk, President of Johns Hopkins University, and James B. Conant, President of 
Harvard, served on the Board. 
The Board of Scientific Directors was responsible for the appointment of the 
scientific staff and for the establishment of general policies concerning the scientific 
investigations, and it did much to keep the research organization performing at a very high 
level. The Director of the Institute (Flexner) was appointed by the Scientific Directors and 
was in intimate contact with the scientific staff. Beginning in 1910, there was also a Board 
of Trustees which had oversight over the financial affairs of the Institute. The distinctive 
role of the Board of Scientific Directors, combined with the skills of Flexner and his 
successor Herbert Gasser, facilitated the recruiting of some of the best scientists assembled 
at that time. Permanent appointments had to be approved by both Boards, though the 
Director appointed non-permanent members of the staff, determined their rank, and fixed 
their salaries. Flexner personally interviewed every scientist, even those who were at the 
Institute for only a single year, before any appointment was made. 
The original Board of Trustees consisted of Rockefeller Jr., Gates, and their lawyer 
Starr J. Murphy. Welch and Flexner served on both the Board of Trustees and the Board of 
Scientific Directors, providing communication between the two boards. The existence of 
two boards lasted until 1953, when the two were merged into a single Board of Trustees. 
Since then, the Rockefeller organization has not had a separate board of world-class 
scientists making the final decisions about personnel. The quality of recruitment, while 
continuing to be of high quality, has not had the same degree of extraordinary consistency 
as during the time when the Institute had a Board of Scientific Directors with distinguished 
scientists intimately involved in making staff appointments and rigorously overseeing the 
scientific research of the Institute. The Board of Scientific Directors met three or four times 
a year at the Institute and focused in great detail on the quality of appointments at the 
Rockefeller. Since 1953 there have been scientists on the Board of Trustees, but they have 
never exercised the same degree of rigorous oversight over the organization’s appointments 
as was the case when there was a separate board for scientific affairs. 
At the Institute, permanent scientists were called Members and had indefinite 
appointments corresponding to professorial appointments in American universities. The 
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next highest title was Associate Member, a three-year appointment renewable for three 
more years. In general, after a second three-year term, Associate Members either were 
appointed as Members or were expected to resign. Associates were appointed for two years, 
and assistants and fellows for one. Eligible for reappointment, scientists in the lower ranks 
left the Institute or rose to higher rank after three to five years. Like the Kaiser Wilhelm or 
Max Planck Institutes, which later had similar promotion policies, the Rockefeller provided 
advanced training for what became the elite of biomedical scientists in America. The 
process of appointment as a Member was extremely rigorous. Not all senior scientists 
received their initial appointments at that level. For example, in 1934, 46 percent of senior 
scientists had initially been appointed to the rank of Member, while 54 percent had been 
promoted from a lower rank. Members rarely left: only one had resigned by the mid-1930s, 
and even he returned. 
Although the Board of Scientific Directors was responsible for the scientific 
policies of the Institute, the research problems under investigation were chosen by 
individual scientists. The Members and their associates and assistants made up groups 
which were called laboratories, and which were grouped into divisions. Funds for scientific 
investigations were made to laboratories and administered by the head of the laboratory, 
though budget allocations were, of course, modified from time to time by special action of 
the Board of Scientific Directors. 
The meetings of the Board of Scientific Directors were held quarterly, and for these 
meetings, the head of each laboratory or division submitted a technical scientific report. 
Discussion of the reports became the most important item of business at the meetings. The 
reports played an important role in communicating to the Board what was going on in the 
Institute. Members of the Board of Scientific Directors generally attended all meetings, and 
they read the reports carefully. Some members of the Board made a habit of consistently 
visiting various laboratories, not in the spirit of monitoring but because of their genuine 
interest in the Institute’s research. An important incentive to be a Board member was the 
opportunity to be informed about the Institute’s research activities (Rivers, 1967: 198). In 
short, the Board of Scientific Advisors played an important role in rigorously evaluating the 
quality of research at the Institute.3 
During the first three decades of the Institute, its overall governance and operating 
procedures were reflections of Flexner’s philosophy, ideals, personal mannerisms, and 
scientific style. The insistence after 1910 that every laboratory throughout each calendar 
                                                 
3 Unpublished and untitled lecture by Simon Flexner, Bronk Papers, Record Group 303.1, Box 6, Simon 
Flexner folder, Rockefeller Archive Center [hereafter RAC]. 
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year prepare periodic and detailed scientific reports for the Scientific Directors was due in 
part to Flexner’s insatiable appetite for learning. As the Institute developed, these reports 
reflected some of the latest trends in science, and provided opportunities for Flexner and 
the Directors to reflect upon what the Institute might do next. Whereas Flexner had been 
primarily interested in infectious diseases when he was at Johns Hopkins during the 1890s, 
by the time of Jacques Loeb’s appointment to the Institute in 1909, Flexner’s cognitive 
framework had significantly expanded to encompass a very broad view of biomedical 
science. He increasingly believed that biomedical sciences must rely primarily on the basic 
sciences of chemistry, physics, and biology and that investigations had to be based on the 
methods of those fields. This change was due in part to the fact that the Institute provided a 
rich learning environment. Flexner held the view that most scientific knowledge is 
interrelated. For him, all forms of life were “related organically and ... united 
physiologically and pathologically.” In the pursuit of knowledge, there should be no 
disciplinary boundaries separating the study of different forms of life, though there had to 
be separate laboratories for purposes of “economy of action” (Clark, 1961: 172).4 
Flexner was very much aware that knowledge changes very rapidly in the global 
world of science, and he believed that if a biomedical Institute was continuously to absorb 
and integrate new knowledge, there had to be an intimate commingling of investigators in 
various fields of science, even if in the short term some fields of biomedical science 
appeared unrelated to others (Flexner, 1930: 461). He believed that the range and scope of 
the Institute should provide considerable scientific diversity. Moreover, the internal 
organization should be highly flexible so that it could quickly adapt to new knowledge. For 
Flexner, the culture within the Rockefeller should be such that the scientific staff would be 
willing to communicate and cooperate with each other. Such a strategy meant that every 
scientist should internalize extensive scientific diversity, and should be able to 
communicate with every other scientist. Indeed, scientific diversity and ability to 
communicate with others on the scientific staff were prerequisites for recruitment. Because 
so many of the scientists were fluent in multiple languages, foreign scientific publications 
were frequently discussed by the staff. And because there were staff fluent in German, 
French, and Russian, foreign scientists were eager to visit the Institute and to discuss 
research of mutual interest. 
Flexner was aware that there was a short supply of scientists who had the kind of 
scientific diversity he wanted to recruit. His strategy was that the Institute over time should 
                                                 
4 See also Simon Flexner to Abraham Flexner, July 4, 1924, Flexner Letters, Flexner Papers, American 
Philosophical Society [hereafter APS]. 
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train a number of its own staff, and during his directorship, the Rockefeller became one of 
the world’s leading centers of training for young postdoctoral biomedical scientists. This 
meant carefully recruiting able young people and providing them with excellent 
opportunities to grow scientifically. He was prepared for the overwhelming majority to 
depart after a few years of training, but the most exceptional were retained. This obviously 
meant that Members were constantly attentive to the strengths and weaknesses of younger 
staff. Although only one in twenty was retained, by 1950 almost half of those with 
permanent Institute appointments had risen through the ranks. 
Flexner’s correspondence demonstrates that he was enormously attentive to the 
well-being of young investigators. Even if they failed in particular investigations, he would 
encourage and console them and give them new opportunities. When a depressed young 
investigator told him that he had accomplished nothing worthy of publication, Flexner 
warmly consoled him by remarking, “Nothing? ... you don’t seem to realize that to have 
nothing is to have something” (Rous, 1949: 427). Flexner was wise enough to know that for 
these young people, coming to the Institute was one of the great experiences of their lives, 
and he frequently encouraged his senior colleagues to make certain that this was the case. 
Even if Flexner did not retain a young scientist, he frequently paid the investigator a salary 
for a year after his departure as an incentive for another academic institution to recruit him. 
This kind of practice let young people know that if they went to the Rockefeller, they 
would have excellent opportunities to find a position upon exiting, and this did much to 
keep a steady stream of able young scientists going to the Rockefeller. 
Over time, hundreds of young people passed through the Institute and went on to be 
prominent biomedical scientists. Flexner was highly committed to upgrading the quality of 
America’s universities and medical schools, and believed that one of the major 
contributions of the Institute was its development of young investigators and teachers for 
universities and medical schools. He was very proud of the fact that by the early 1920s, the 
leading American universities in the country eagerly sought the Institute’s young 
investigators (Rous, 1949: 425). 
With so many scientists passing through the Institute, some errors in judgment were 
made. Not everyone retained was of world-class distinction, but probably no other research 
organization in the world had such a high proportion of the scientific staff eminent in 
biomedical science. Moreover, the Institute encouraged a few scientists to depart whom it 
should have kept. One such scientist was Michael Heidelberger, who because of his 
exceptional qualities was at the Institute for a very long period (1912 to 1927, except for a 
short period during World War I), but was eventually encouraged by Flexner to leave for 
fear that he was not getting sufficient recognition for his many achievements, which were 
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invariably coauthored with a senior scientist. In the words of Elvin Kabat, Heidelberger 
was a “Leonardo da Vinci-type Renaissance man ... who became the father of quantitative 
immunochemistry” (Kabat, 1992). 
As Director, Flexner also worked to maintain close research communication with 
members of the original Board of Directors and the subsequent Board of Scientific 
Directors and the Board of Trustees, and this was important in promoting trust among those 
governing the Institute. This was especially important in the development of a cohesive 
culture in the history of a new organization. Flexner and Christian Herter became intimate 
friends, and their families visited one another’s homes. The Flexners and the Herters had 
summer houses at Seal Harbour and one of Flexner’s sons married one of Herter’s 
daughters. With Hermann Biggs, Theobald Smith, and Emmett Holt, Flexner’s relations 
were somewhat formal, though they became closer over time. He was especially respectful 
of Smith’s scientific knowledge, and he wrote a book with Holt on dysentery in infants 
(Rous, 1949: 421). Among the trustees, Flexner developed a very warm relationship with 
Gates, and the Flexners frequently visited the Gates home in New Jersey and their summer 
house on Lake George. Over time, he also developed a close relationship with Rockefeller 
Jr. As Mrs. Flexner and Mrs. Rockefeller liked each other, the Flexners frequently joined 
the Rockefellers at their New York City residence and were invited from time to time to the 
family estate at Pocantico Hills. 
More than anyone else, Flexner institutionalized a culture of excellence within the 
Institute. Throughout his directorship, he did not become a full time administrator but 
continued to work in the laboratory (Rous, 1948: 613). Within the Institute, he was usually 
too busy to engage in small talk. He set very high standards not only for himself but for 
everyone around him. In some respects, he was a bundle of contradictions. He could be 
extraordinarily charming, but if he believed the situation called for it, he could be coldly 
blunt. He tended to be extremely instrumental in his dealings with the scientific staff. He 
was willing to be very harsh with individuals if he believed this was the most effective way 
of getting “the most out of a man and was best for his development” (Clark, 1961: 172). On 
the other hand, he worked tirelessly to establish a nurturing environment in the Institute. 
Overall, he was a very considerate and affectionate individual. He kept in touch with the 
lives of most everyone in the Institute, and all staff—scientific or otherwise—usually 
received birthday or wedding anniversary cards. He was solicitous of the needs of the 
nurses, secretaries, porters, laboratory helpers, keepers of animals—all of the unheralded 
people essential for a high quality research organization. When they encountered family 
emergencies, he would help them cope with the problem—financially if appropriate (Rous, 
1949: 427; Cohn, 1948: 228; Rivers, 1967:123–127). 
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On the other hand, there is evidence that during the Flexner years, the Institute was 
often conservative—if not outright “stingy”—with regard to salaries. In part, this practice 
stemmed from Flexner’s fear that universities would accuse the Rockefeller Institute of 
stealing faculty by paying inflated salaries. This did not happen: Rather, it was the 
universities which from time to time attempted to lure Rockefeller Members away with 
extremely high salaries. Because he was concerned for the welfare of American 
universities, Flexner was determined to keep Institute salaries within the range of American 
salaries at high quality universities (Rivers, 1967: 124–125; Rous, 1949: 425). For research 
expenses within the Institute, however, the situation was different. In comparison to the 
leading universities in America, Institute scientists had generous research funding from the 
Director. 
Funding for research was administered by Flexner in a somewhat personalistic style. 
Even so, the decision-making process about funding research within the Institute was in 
some respects more effective than that which currently exists in most contemporary 
American funding agencies. Investors the world over seek information about the quality 
and safety of their investments. Flexner had a great deal of information about the research 
potential of almost everyone in the Institute, and he and his colleagues on the Board of 
Scientific Directors were in an excellent position to make well-informed decisions about 
what was high-risk and low-risk research, who had the abilities to conduct a high-risk, 
long-term project and who did not. Moreover, they were well positioned to monitor 
investments in scientific research, as a result of periodic scientific reports and their ability 
to discuss and advise on the progress of specific research projects. This, of course, was 
sound investment strategy: It meant well informed investors very knowledgeable about the 
level of risk represented by those in whom they were investing and with high capacity to 
monitor their investments. The fact that the Journal of Experimental Medicine and other 
high-quality journals were edited at the Rockefeller provided the Director with a great deal 
of information about papers produced at the Institute. In sum, the Institute strategy for 
funding science was highly flexible because of the large amount of information possessed 
by those making scientific investment decisions.5 
From the very beginning, the culture of the Institute was entrepreneurial and high-
risk oriented. Flexner regarded trivial and unimportant research with contempt. He had no 
                                                 
5 The process of funding science at the Rockefeller was very different from the process of funding science 
by the National Science Foundation and the National Institutes of Health in contemporary America. With 
numerous proposals arriving before study groups and program officers, these two organizations are less well 
positioned to assess the degree of risk involving a researcher and a research project. The NSF and NIH grant 
proposal submission process and the decision-making process about research funding have become more 
standardized and bureaucratized, with the consequence that much high-risk research tends to be discouraged. 
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objection if labs were unproductive for lengthy periods of time, as long as they were 
addressing important problems. He would wait a long time before concluding that a young 
scientist was not suitable for the Institute. Mindful of the weakness of his own early 
education, he took the view that one of the missions of the Institute was to provide research 
training for young postdocs. And because of the Institute’s rich scientific diversity and the 
excellent internal communication among the scientific staff, he frequently encouraged 
scientists to move into totally new fields of research. On one such occasion, he informed a 
young scientist who was moving to a new problem that it would take at least two years to 
begin to understand its parameters: “I will not expect anything of you until after that.” 
Flexner’s ability to identify and fund new areas of research—as with the work of Peyton 
Rous—was emblematic of the Institute’s capability to anticipate new directions, even 
radically different directions, and move into them rapidly (Rous, 1948: 612; Jones, 1946: 
295; Rous, 1949: 424). 
On almost all occasions, Flexner was available as both an intellectual and scientific 
resource. In a number of cases, he went out of his way to inform young investigators that 
they needed an assistant and that he would provide the funding (Rous, 1949: 424). At the 
height of the depression, when Tom Rivers told Flexner that he needed extra funding for his 
research (though he did not specify the amount), “without batting an eye” Flexner provided 
$10,000, a great deal of money at the time (Rivers, 1967:121). On the other hand, Flexner 
did not hesitate to be stern—even with a senior Member—if he believed the person was not 
being prudent with the resources provided by the Institute.6 
Gates and the two Rockefellers did much to set the tone for the research strategy of 
the Institute. From the beginning they had informed the original Board of Directors that 
they expected no short-term utilitarianism or results. Indeed, Gates and the Rockefellers 
had early concluded that no important discoveries were likely to result from the Institute. 
Their major hope was that the Institute would conduct high quality research, be a training 
ground for young investigators, and serve as an example for other philanthropists. Research 
on important problems, even if long periods of incubation were necessary, was encouraged 
from the outset (Gates, 1977; Fleming, 1954: 157). Thus, without pressure to produce 
results in the short term, Flexner could encourage his staff to “think big,” to take risks, but 
to be aware that rigorous standards of excellence would be the criteria by which all results 
would be assessed.  
From the beginning of the Institute, Welch, Flexner, and others on the Board of 
Scientific Directors had advocated a research program on animal pathology, in part because 
                                                 
6 Simon Flexner to Phoebus A. Levene, November 30, 1931, Simon Flexner Papers, APS. 
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certain diseases are transmissible from animals to humans. Unanticipated events in 1913—a 
widespread outbreak of hog cholera—brought the issue to the fore. After studying the 
matter, Flexner and Theobald Smith of the Harvard Medical School proposed that the 
Institute create a full-scale department of animal pathology, to which the Board agreed. 
Because of his distinguished international reputation, Smith was asked to head the new 
department, and the decision was made to locate the department in the Princeton, New 
Jersey area. In 1917, the Institute’s Department of Animal Pathology opened with a state-
of-the-art facility, and with a faculty that grew to be an integrated scientific community 
with research and social life tightly intertwined (Kay, 1986: 454; Corner, 1965: 134). 
The new department at Princeton was almost the equivalent of establishing a new 
institute. Organizationally under the direction of Flexner, the department’s day-to-day 
operations, most staff appointments, and local policies were under the direction of the local 
head (Smith). The Princeton department had scientific leadership with a vision of how to 
address “doable” major problems, with the capacity to identify scientific talent from diverse 
fields, and able to integrate this scientific diversity in a rigorous but nurturing environment. 
As well, the Princeton site had scientific diversity, scientific depth, scientific integration, 
and high-quality staff. Significantly, a number of major discoveries did occur in the 
Princeton branch of the Rockefeller Institute, breakthroughs which resulted in Theobald 
Smith’s being awarded a Copley Medal and John Northrop and Wendell Stanley receiving 
Nobel Prizes in Chemistry for separate research conducted in the Princeton laboratories 
between 1917 and 1937. However, these recognitions are only a part of the story of the 
Princeton department. 
Smith was a very cautious director of research and, unlike Flexner, risk-averse. 
Thus, he added relatively few staff who did not complement his immediate research 
interests. However, because Flexner exercised scientific oversight over the Princeton 
department, he was able to counterbalance Smith’s conservative tendencies, with fortuitous 
consequences for the Princeton program. This occurred most dramatically in the career of 
John Northrop, one of the most innovative scientists during the first forty years of the 
Institute. Though the Princeton department focused on animal diseases, Flexner arranged 
for Northrop to move to the Princeton site in 1926, even though he clearly did not focus on 
animal diseases. 
Flexner’s moving Northrop to Princeton contributed to a creative research program 
which culminated in Northrop’s being awarded a Nobel Prize for Chemistry in 1946. At the 
Rockefeller Institute, Northrop had worked closely with Jacques Loeb, who taught him how 
to design complex experiments in order to answer important, well-focused questions. He 
also influenced Northrop to be interested in the colloidal properties of proteins and to work 
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on pepsin and trypsin. Northrop was a creative and highly productive scientist with a 
magnetic personality, and over the years he attracted a number of first-rate scientists to his 
lab (de Kruif, 1962: 3–35). Using solubility measurement, ultracentrifuge analysis, and 
electrophoresis, Northrop and his colleagues demonstrated that pepsin is pure enzyme, thus 
challenging the then dominant views of Richard Willstätter about enzymes. As a result of 
the work of Northrop’s lab as well as that in the Institute’s New York labs, Rockefeller 
investigators “led the world” in enzymology by the early 1930s (Olby, 1974; Herriott, 
1962: 4–5). 
By the time of Smith’s retirement (1930), Flexner had decided that the Institute 
should have a program in plant pathology, also located at Princeton. He believed that a 
program on plant disease—especially plant viral diseases—would be of enormous benefit 
to the Institute (Flexner and Flexner, 1941: 295–296; Corner, 1965: 313). One of the 
nation’s leading plant pathologists, Louis O. Kunkel, was appointed to head a program in 
plant pathology, with a mandate to study plant diseases caused by bacteria, fungi, and 
viruses. Kunkel decided to concentrate on tobacco mosaic virus (TMV), and to tackle his 
research program he recruited a diverse group of talented young scientists—including 
Wendell Stanley—who could work on most aspects of the biology of TMV.  
Stanley’s training had made him a promising investigator in physiological 
chemistry, but he was devoid of training on viruses. At the time Stanley began his work, no 
one had previously isolated a virus. Stanley assumed that the virus was protein, and in the 
small Princeton environment, he quickly became very familiar with the work of Northrop’s 
lab, which had demonstrated that enzymes were crystallizable and were proteins. Thus, 
Stanley set out to discover if viruses could be purified by methods similar to those used by 
the Northrop group (Pirie, 1969: 232–233; Edsall, 1971; Stanley, 1964). Several years of 
hard work and more than one hundred chemical reagents later, Stanley reported that he had 
isolated a “protein” virus, and after further purification he obtained highly infectious 
needle-like crystals. In a 1935 paper, he reported that he had “strong evidence that the 
crystalline protein herein described is either pure or is a solid solution of proteins” (Stanley, 
1935). “No discovery made at the Rockefeller Institute, before or since, created such 
astonishment throughout the scientific world as this” (Corner, 1965: 320). Immediately, 
Stanley became a national celebrity. For many, he was raising fundamental problems about 
life, just as Jacques Loeb had earlier done at the Institute. Because Stanley’s 1935 paper 
attracted so much attention in the popular media, it naturally stimulated great interest in the 
scientific community, and criticism was not long in coming. From Britain, researchers 
reported that TMV was not a pure protein, as reported by Stanley, but contained 
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approximately six percent nucleic acid (RNA), and that it was a nucleoprotein. Why had 
Stanley missed the RNA? 
Over the years, Stanley was subjected to severe criticism both for missing the RNA 
in his paper and for not recognizing that the “crystals” were paracrystalline in nature (Kay, 
1986; Pirie, 1969; 1986). Yet when Stanley began his research in 1932, the true nature of 
viruses was still a mystery. It had not been established whether they were inorganic, 
hydrocarbon, carbohydrate, lipid, or protein. No one had isolated them as such. Though 
Stanley’s 1935 paper had its shortcomings, it was a major step forward in the field of 
virology. Later, with input from the Swedish scientist Thé Svedberg, Stanley was able to 
extend his work and publish a portrait of the rod-shaped TMV. By 1946, largely due to 
Stanley’s initiatives, work on the concentration and purification of different viruses was 
proceeding in several laboratories, and over a dozen viruses had been obtained in highly 
purified form, primarily by the techniques of high-speed centrifugation.  
Having a distinguished program established at Princeton—a program initially 
focused on animals and then incorporating research on plants—not only brought new kudos 
to Rockefeller scientists, but brought to the fore whole new lines of inquiry. To some 
extent, the local circumstances at Princeton mimicked the New York example of intense 
and frequent communication among scientists of very diverse interests, although internal 
disagreements were also a part of the Princeton locale. In establishing an off-site program, 
the Rockefeller Institute took a gamble, acting somewhat precipitately in choosing the 
Princeton location.  
The Institute also took the lead in enhancing scientific excellence in America by 
editing and publishing journals. By developing journals of the highest quality and 
encouraging the staff to publish in them, the leadership of the Institute further emphasized 
its independence from the existing institutional environment. The Journal of Experimental 
Medicine (founded by Welch) was the first journal to be edited at the Institute. Flexner 
became the editor in 1904, and in addition to all his other responsibilities he was chief 
editor for fifteen years, though assisted at the outset (1904–1910) by Eugene Opie. 
Eventually, he asked Peyton Rous in 1921 to be coeditor, and Rous essentially functioned 
as the editor for the next thirty-six years, though Flexner continued to be listed as coeditor 
until his retirement as the Institute Director. Flexner’s successor Herbert Gasser served as 
coeditor from 1935 to 1953, the entire period for which he was Director (Corner, 1965: 62–
63; Flexner and Flexner, 1941: 243–250; Dulbecco, 1976: 275; Andrews, 1971: 653; 
Robertson, 1953: 25). 
In 1918, Jacques Loeb, with John Osterhout of Harvard, launched the Journal of 
General Physiology, which was subsidized by the Rockefeller. With Institute support, Loeb 
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also launched a monograph series designed to advance the development of experimental 
biology from a quantitative and physiochemical point of view. Through these publications, 
Loeb helped to unite various fields of biology by breaking down barriers among different 
specialties (Pauly, 1987: 150; Blinks, 1974: 213). The Institute also published numerous 
other monographs, sometimes at irregular intervals. There was a series entitled Studies 
from the Rockefeller Institute for Medical Research, which by 1930 had seventy volumes 
of 600 pages each. The Journal of Biological Chemistry also was published by the Institute 
for many years, and Phoebus Levene, Donald Van Slyke, and others at the Institute 
published a high proportion of their papers there (Tipson, 1957; Wolfrom, 1961: 1319; 
Herter, 1910).  
During the more than thirty years that he served as Director of the Institute, Flexner 
played a major role in improving the quality of the Institute’s publications. These aided the 
productivity and creativity at the Institute and were important in drawing attention to the 
Institute’s accomplishments. Over the longer term, probably no journal has had greater 
impact in establishing new trends in biology than the Journal of Biophysical and 
Biochemical Cytology, later renamed the Journal of Cell Biology. This was another journal 
which was published at the Institute, and its founding was due to the inspiration of Keith 
Porter and the strong support of Herbert Gasser (Palade, 1977). 
The experience of the Rockefeller Institute demonstrates that diversity and depth of 
knowledge in a well-integrated research organization have the potential to change the way 
people view problems and to minimize their tendency to make mistakes and/or to work on 
trivial problems. Frequent and intense interaction among people with low levels of diversity 
tends not to lead to major breakthroughs, but if scientists work in environments where there 
is moderately high scientific diversity and depth, and have frequent and intense interaction 
with those having complementary interests, they increase the probability that the quality of 
their work will improve. It is the diversity of disciplines and paradigms to which 
individuals are exposed in frequent and intense interactions that increases the tendency to 
develop new ways of thinking about fundamental problems. For such a process to continue 
over the longer term, the organization must not only provide the stimulation, resources, and 
environment for today, but also, in a sense, anticipate the future by undertaking whole new 
lines of research.  
Intellectual and social integration were maintained at the Rockefeller Institute by a 
variety of devices. Eating meals together while conversing about serious scientific matters 
was an important part of the Rockefeller culture and an important means of integrating the 
scientific diversity and depth of the Institute. There was good food at lunch, served at tables 
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for eight. The idea was that a single conversation could take place at such a table, but not at 
a larger one. 
The degree of intellectual and scientific diversity was much lower at the Rockefeller 
Institute than that at the colleges of Oxford and Cambridge, where eating at “high table” 
was also an important part of the culture. At the English colleges, diversity ranged all 
across the board (e.g., from archaeology and ancient and modern languages to chemistry, 
physics, biology, and mathematics). With so much diversity, it was considered poor 
etiquette to talk about one’s work at the “high” table of the colleges, as many of those 
present would be unable to comprehend the line of discussion. At Rockefeller, in contrast, 
diversity was only within the biomedical and related sciences, and the norm was to carry on 
lively lunchtime discussions about these fields. The lunch table was a great learning 
experience where people had intense discussions about new approaches to research. Indeed, 
these luncheon experiences led not only to new factual information and changes in 
philosophical viewpoints, but also to collaborative research projects across fields (Dubos, 
1976: 31). Without the kind of culture exemplified in the lunch experiences at the Institute, 
some of the major discoveries made at the Institute would not have occurred. 
For many, the lunch table at the Institute was the high point of the day. Paul de 
Kruif, a scientist at the Institute who later became a strong critic, nevertheless thought the 
dining room was one of its most stimulating characteristics. 
... at the lunch break there was balm for my discouragement. Here I could 
listen to the scintillating talk of my betters. ... I never tired of listening to the 
philosophy of Alexis Carrel, who had won the Nobel Prize in medicine ... 
Carrel, who had been in America a long time, had carefully preserved his 
French accent, which made him sound to me even more learned than he was 
... Then at the luncheon table there might be Dr. Peyton Rous, refined, 
gentle, exquisitely cultured ... In this refectory there was an air of solemnity 
to be expected and appropriate to the unveiling of mysteries (de Kruif, 
1962:16–17).  
 
And in the words of Dubos: 
There never was a symposium—in the etymological sense of 
the word ... that was more scientifically productive and 
intellectually pleasurable than those held daily in the lunch-
room of the Rockefeller Institute, though coffee and ideas 
were the only intoxicants (Dubos, 1976: 31). 
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Apart from lunch, scientific integration was also facilitated by the Friday afternoon 
lecture which everyone was expected to attend, when Institute investigators or 
distinguished scientists from all over the world reported about their work. In the Hospital 
Department, there were afternoon tea times which most scientific staff attended.  
One of the most important integrating devices was the journal club, especially the 
Hospital Journal Club which generally met twice a month. Everyone was expected to 
attend, and to be prepared to report on a paper outside their own research field, but of 
general interest to everyone. No one knew in advance who would be called upon to present 
materials to the journal club. Why would world-class scientists agree to participate in such 
activity? They did so because they knew they were members of an extraordinarily 
distinguished organization, and they believed that one reason it was so outstanding was that 
they were continuously learning from each other. This kind of regular reading outside one’s 
own specialization and in areas of interest to others in the organization was one way of 
integrating scientific diversity. In short, the Institute had developed a culture of continuous 
learning for its scientists. 
Its learning environment was supported by being located in New York City. Before 
World War II, most distinguished foreign scientists traveling to America arrived in New 
York and invariably visited the Rockefeller Institute. Certainly no other biomedical 
research organization in America was so favored with foreign scientists. It was in the 
neighborhood of the New York Hospital-Cornell Medical Center and across town from 
Columbia University’s medical center. By 1930, New York City had become a leading 
center of biomedical science, and this environment provided an opportunity for access to 
many of the latest ways of thinking about biomedical science. If this small institute could 
not have all the diverse ways of approaching biomedical science represented on its 
permanent staff, it was in the fortunate position of having many of the world’s leading 
scientists passing through with reports about their work. Moreover, Rockefeller Foundation 
grants to young British and European scholars brought to New York the cream of the crop 
of young scientists, for stays of varying lengths.7 
Institute scientists took great pride in being associated with what many viewed as a 
temple of science (de Kruif, 1962: 13). Even today, as soon as one crosses from York 
Avenue on the upper east side of Manhattan onto the grounds of the Rockefeller, one is 
aware of being in a sanctuary, separated from the hustle and bustle, the grime and dirt, the 
                                                 
7 The Rockefeller Foundation was a completely separate organization from the Rockefeller Institute. Over 
the years, only a very insignificant amount of funding went to the Institute from the Rockefeller Foundation, 
and during the Flexner years there was often a fair amount of tension between Rockefeller Foundation officers 
and Flexner (Kohler, 1991). 
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shouting and cursing of the city. The original idea of the Institute had been conceived in 
part by a religious minister, Gates, and throughout the century, some observers referred to 
the Institute in religious terms. Not only for Gates, but also for the Rockefellers, Flexner, 
and Welch, biomedical science acquired almost religious proportions. 
How did this happen? Gates spoke for the two John D. Rockefellers when he wrote 
that “disease is the supreme ill of human life and is the main source of almost all other 
human ills: poverty, crime, ignorance, vice, inefficiency.” He went on to explain that these 
ills could not be cured by the economic and social restructuring of society, as many 
socialists believed. Rather, society’s problems were technical in nature and required 
technological solutions, which medical science could provide (Berliner, 1977: 7, 1986). For 
Gates, these views had a religious quality to them, for scientific medicine was the means of 
building a new and better world, of uplifting and civilizing one’s fellow men. The 
Rockefeller Institute should become the functional equivalent of a temple for the new 
religion, and medical investigators were to be the equivalent of priests who would reduce 
suffering and poverty. Gates referred to the Institute as a theological seminary and Flexner 
as a scientific “Doctor of Divinity.” Indeed, de Kruif thought “Flexner looked as if he 
might be high in the College of Cardinals” (de Kruif, 1962: 12; Brown, 1979: 125; Pauly, 
1987: 136). And in writing about the Institute, de Kruif reported that for Flexner, the 
greatest achievement of the Institute was not “the scientific output, its undoubted saving of 
lives, its contributions to basic knowledge,” but rather “it was the harmony, the serenity, the 
brotherhood with which the staff had always worked together” (de Kruif, 1962: 56).  
Welch had early on advised Flexner to recruit scientists “who agree well together” 
(Rous, 1949: 425). Both believed that new ways of thinking about scientific problems were 
most likely to emerge in a scientific environment in which scientists had intense and 
frequent interaction with one another, so that a fundamentally new way of thinking about a 
problem could occur. For them, an environment of harmony, trust, and dignity was 
essential, for whether one was in a religious or scientific monastery, the priesthood must be 
passionate in its quest for the truth. Thus, in recruiting staff for such a sanctuary of science, 
it was important to select individuals who were imbued with a spirit of cooperation and to 
avoid the prima donnas. 
To recruit staff who would pursue problems on a large scale, Flexner thought it was 
important to find scientists concerned with deep philosophical problems. During the first 
half century of its existence, the Institute had a number of scientists who not only 
internalized vast scientific diversity but whose scientific thinking was well integrated with a 
rich philosophical framework. This kind of scientific staff generated enormous excitement 
at the Institute lunch tables, which became famous over much of the world. As in most 
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“monasteries,” there was some conflict. In fact, some Members cared little for others. But 
relative to most research organizations, there was a high degree of communication and 
cooperation among the scientific staff, and this contributed to its rich learning environment 
(interviews with Edelman, Hotchkiss, and Ris). 
In 1935, Flexner at age seventy-two retired as Director of the Institute after more 
than thirty years of service. Though he had been able to recruit only a “motley” group of 
scientists at the outset, by the time he stepped down as Director, the Institute had emerged 
as one of the world’s leading centers of biomedical science. Whereas in the first decade of 
the century, most scientists with established reputations would not have considered 
accepting an appointment there, the Institute had now long eclipsed the Pasteur Institute, 
the Lister Institute in London, and others. During the years that Flexner served as director, 
ten scientists had done research at the Institute which resulted in their receiving recognition 
for major discoveries in biomedical science. Five (Alexis Carrel, Karl Landsteiner, John 
Northrop, Peyton Rous, and Wendell Stanley) had done work at the Institute which resulted 
in their receiving a Nobel Prize either during or after Flexner’s tenure. Theobald Smith 
received the Copley Medal for research which he did at both the Institute and at the 
Harvard Medical School. Oswald Avery, Simon Flexner, Jacques Loeb, Theobald Smith, 
and Hideyo Noguchi made breakthroughs which resulted in their receiving numerous 
nominations in multiple years for a Nobel Prize in Physiology or Medicine, enough to meet 
the criteria established in Appendix One as major discoveries. During the Flexner years, no 
other research organization in the world had more major breakthroughs in biomedical 
science than the Rockefeller Institute, and no research organization in the world since then 
has had so many major breakthroughs in a comparable period of time (thirty-four years). 
During the Flexner years, the Institute had distinctive advantages in identifying both 
junior and senior talents throughout the world. Although the Rockefeller Foundation was 
not a major funding agency for the Rockefeller Institute, the Rockefeller Foundation had 
become a major funding source for biomedical science throughout Europe and North 
America. To gather information about the quality of scientists and their labs, the 
Foundation obtained extensive reports about research in every major biomedical research 
organization in Europe and North America. Because he was a trustee of the Foundation and 
because his brother Abraham had a long affiliation with the Foundation, Simon Flexner had 
extensive knowledge about “who was up and coming” on both sides of the Atlantic, and 
was in a strategic position to invite outstanding young scientists to the Institute. Similarly, 
his prominence in the National Research Council provided him with inside information 
about many promising young scientists (Kohler, 1991). 
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During the 1920s, aspiring biomedical scientists in America took the view that they 
needed to spend at least two to three years at the Institute for postdoctoral training. By 
1935, more than 150 Rockefeller-trained scientists had become professors in America’s 
leading universities and were beginning to establish their own training programs, a process 
which in the longer term would narrow the gap in quality between the Rockefeller Institute 
and other organizations in biomedical science. But until the National Institutes of Health 
became the leading training center for young biomedical scientists during the 1950s and 
1960s, the Rockefeller Institute was clearly the major American center for postdoctoral 
training in the biomedical sciences, with younger people also from Europe increasingly 
going to the Institute for advanced training. By the time of Flexner’s retirement, the 
Institute had become not only a world-class center for research, but also a major center for 
advanced training. Without obligations to train either undergraduates or graduate students, 
it was a very serious center for advanced training for only the best of the best. When future 
Nobel laureate Alan Hodgkin went there in 1938 from the University of Cambridge, he was 
struck by the very high quality of its scientists, its instrumentation, and its greater formality 
and seriousness as compared to Cambridge (Hodgkin, 1977, 1992). And when the 
distinguished bacterial physiologist Marjory Stephenson of the University of Cambridge 
completed her visit to the Rockefeller Institute in 1931, she wrote the Secretary of the 
Medical Research Council, Walter Fletcher, that research in bacterial chemistry at 
Cambridge and Oxford was years behind. She was especially impressed with the way that 
enzymology and other areas of biochemistry had become integrated with bacteriology at 
Rockefeller: “It saddens me to think that there is no work at all of this kind even beginning 
in either of the two great places for bacteriology in Cambridge and Oxford” (quoted in 
Kohler, 1985: 180). This contrast between science at the Rockefeller and Cambridge was 
also very disappointing to Fletcher, who had worked for years to break down disciplinary 
boundaries at Oxford and Cambridge (Kohler, 1978, 1985, 1991). 
 
 
THE DIRECTORSHIP OF HERBERT GASSER 
 
Among the reasons for the continued excellence of the Rockefeller Institute were its 
flexibility, derived in large part from its autonomy, and its independence from the 
institutional environment in which it was embedded. Unlike many research organizations at 
the time in both Europe and America, it was not dependent on external funding, and was 
therefore immune to the kinds of constraints which funding sources place on organizations 
(Hollingsworth and Hollingsworth, 1988). Until the mid-1950s, the Rockefeller Institute 
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never accepted grants or any funding from sources other than the Rockefeller family. 
Moreover, it was relatively autonomous from the norms and rules imposed by most 
scientific disciplines. Most universities, organized around academic disciplines and their 
academic departments, are constrained in their behavior by the norms and rules of existing 
academic disciplines. But because the Rockefeller Institute was organized around 
laboratories rather than around scientific disciplines and fields, it had a greater capacity to 
be flexible and to adapt quickly to new research strategies. And in contrast to the 
institutional environment in Germany and France, the Rockefeller Institute had a high 
degree of autonomy to appoint anyone to its staff. In Germany, in contrast, most scientists 
who became professors first had to qualify by having the German habilitation. But the 
Rockefeller could and did appoint as Members scientists who were trained in many parts of 
the world. 
The Institute was still performing well when Flexner retired, but it was in need of a 
new director with different scientific perspectives. Even high performing research 
organizations undergo demographic changes and need new leadership from time to time in 
order to become better adapted to the fast pace of scientific change. And in the case of the 
Rockefeller, a number of the original members of the Scientific Board of Directors had died 
(Biggs in 1923, Holt in 1924, and Prudden in 1924), as had some of its most distinguished 
scientific investigators (Meltzer in 1920, Loeb in 1924, Noguchi in 1928, and Theobald 
Smith in 1934).  
During the 1930s, the Institute was one of the world’s leading centers in 
enzymology, virology, bacteriology, and pathology. Indeed, there have been suggestions 
that Herbert Gasser, the next director, was appointed to succeed Flexner in an effort to 
prevent the Institute from becoming too narrowly concerned with virology and bacteriology 
(Rivers, 1967: 195–196; Olby, 1974: 183). Even though the Institute had attained a high 
level of excellence in a number of areas of biomedical science, it had clearly made no effort 
to cover all fields of biomedical science. Flexner believed that an effort to work in too 
many fields would lead to uneven quality, and that research programs of low quality would 
bring down standards of excellence in the entire organization (Flexner, 1939). Hence, 
during the Flexner years the Institute had made few or only modest efforts to conduct 
research in a number of areas in which other research organizations in either Europe or 
America had already become quite prominent (e.g., research in vitamins and other areas of 
nutrition, endocrinology, genetics, neurophysiology). Flexner’s strategy had been to have 
areas of core competence which were complementary and to avoid excessive scientific 
scope and diversity, lest the organization become less integrated and have less 
communication among its various component parts.  
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The decision to bring in an outsider, Gasser, as the new director was a wise one. 
Many organizations—because they have a distinctive culture—tend to choose their new 
leaders from within, but such choices may well enhance organizational inertia and hamper 
the organization’s capacity to adapt to the fast-changing environment. Of the eight 
directors/presidents since the founding of the Institute, seven were recruited from the 
outside, and the sole exception, Torsten Wiesel, spent most of his career elsewhere, moved 
to Rockefeller University at the age of sixty, and had been at Rockefeller for less than ten 
years when he was appointed as President. The Rockefeller organization has been much 
more flexible in adapting to new strategies and different styles of science than would have 
been the case had it recruited its directors and presidents from among people who had spent 
most of their careers there.  
Gasser, like Flexner, had grown up in America’s heartland. He was born in 1888 in 
the small town of Platteville, Wisconsin, attended the University of Wisconsin in Madison 
and studied physiology there with Joseph Erlanger, and later was a student at the Johns 
Hopkins Medical School. He then became a colleague of Erlanger, who had moved to 
Washington University in St. Louis, and by 1921 Gasser had been appointed professor of 
pharmacology. Gasser went to London (1923–1924) to work with A.V. Hill, the 
neurophysiologist who was awarded the Nobel Prize in Physiology or Medicine in 1922. 
He also developed a close collegial relationship with Henry Dale and Edgar Adrian, both of 
whom were awarded Nobel Prizes in the 1930s. In the longer term, these relationships were 
important in establishing a network between British neurophysiologists and the Rockefeller 
Institute. Gasser later moved from St. Louis to New York to be Professor of Physiology at 
the Cornell Medical College, and as a result of being in the neighborhood of the Institute, 
he became quite familiar with it.  
Like all subsequent directors or presidents of the Rockefeller, Gasser worked to 
preserve the culture which Flexner and his colleagues had developed. However, Gasser had 
his own distinctive style of doing science, and this was enormously beneficial in facilitating 
the Institute’s adaptation to changes in the world of science. Like Flexner, Gasser made 
continuous efforts to extend the scope and depth of his knowledge. The more he observed 
increasing specialization in science—especially in American universities—the more he was 
motivated to contain the centrifugal forces of differentiation within research organizations 
by promoting the unity of the biomedical sciences. His ideal of an outstanding scientist was 
someone who internalized considerable intellectual diversity, and who was a theorist, an 
experimenter, a builder of instruments, and an artist. Indeed, he believed that at the Institute 
there should be serious efforts to blend humanistic and scientific knowledge, and that great 
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scientists tended to internalize and integrate both humanistic and scientific knowledge 
(Adrian, 1963, 1964; Bronk, 1963).  
A major difference between Gasser and Flexner was Gasser’s greater concern with 
methods of measurement. By building on his awareness of the new initiatives in 
measurement in the field of neurophysiology, Gasser extended the kinds of problems 
pursued in existing kinds of research and steadily pushed the organization into new lines of 
work. This was an example of a major change at the Institute, folded into ongoing 
programs. Reaching maturity during the early days of electronics, he attempted to master 
areas of physics with implications for biomedical sciences. In his own work, he was at the 
frontier of using electronic amplifiers and recording for observing the most minute signs of 
nerve action. As director, he demonstrated that he was attuned to the latest methods and 
ideas in the biological sciences. 
When Gasser became Director, the United States was experiencing the worst 
depression in its history, and this had some adverse effects on the Institute. Even before 
Gasser arrived, Flexner had written to Rockefeller Jr. assuring him that over the next 
several years the Institute would be especially frugal and would not ask for additional 
funds. As a result of the fiscal problems brought by the depression, Gasser was severely 
limited in terms of the new fields of science which he attempted to introduce at the 
Institute. Salaries were tight, and when young scientists left the Institute, most were not 
replaced. Between 1935 and 1941, the total scientific staff of the Institute declined from 
134 to 105. During the depression, the income from the Institute’s endowment fell 
dramatically, with the result that in 1939 the Institute’s expenses exceeded its income by 23 
percent. The Institute was able to cover its deficit only because it had accumulated a surplus 
during the Flexner years (Rivers, 1967: 580–581; Corner, 1965: 329–332). 
Partly due to the economic problems of the depression followed by the disruption of 
wartime, Gasser modified the Institute’s strategy with regard to younger scientists. During 
the Flexner years, when a Member left the Institute his lab had been closed, but on several 
occasions Gasser was willing to permit a remaining Associate Member to head a lab and to 
develop a research program. Both Flexner and Gasser were willing to take risks with 
younger scientists, but Gasser was more inclined to grant some young scientists a high 
degree of autonomy in developing their own research programs. The strategy paid off 
handsomely in the cases of several younger scientists who later made major discoveries 
which began at the Rockefeller organization (e.g., Henry Kunkel, Stanford A. Moore, 
George Palade, Keith Porter, William H. Stein). Among these scientists, there were 
subsequently three Nobel Prizes, two Lasker Prizes for Basic Biomedical Science, and two 
Horwitz Prizes for research conducted at Rockefeller (interview with Palade). 
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Despite the budget constraints, Gasser provided leadership for altering the research 
strategies of the Institute. As retirements occurred, the research emphasis on bacteriology 
and infectious diseases, paramount during the Flexner years, decreased. Gradually, Gasser 
was facilitating the development of different research programs. One of the most 
significant, with long-term consequences, was neuroscience. Rather quickly, Gasser 
developed a program in neurophysiology which focused on the fundamental properties of 
nerve cells, dendrites, and the primary synaptic endings of nerve fibers. He surrounded 
himself with several competent foreign investigators—Harry Grundfest from Russia, Rafael 
Lorente de Nó from Spain, David Lloyd from Oxford, and Jan Friedrich Toennies from the 
Berlin Technische Hochschule. By the late 1940s, three scientists from the neurophysiology 
group held the rank of Member: Gasser, Lloyd, and de Nó (Hodgkin, 1977: 7–8; Corner, 
1965: 332–340).  
While the work for which Gasser was to win the Nobel Prize had been done at 
Washington University before he arrived at the Rockefeller, he did lay the foundations for 
work in neurophysiology which over the decades would evolve into a rich neuroscience 
program at the Rockefeller. His successor as Director of the Institute—Detlev Bronk—was 
also a neurophysiologist who built on the foundations laid by Gasser. This tradition led to 
H.K. Hartline’s work in the neurophysiology of vision, which was awarded a Nobel Prize 
for Physiology or Medicine in 1967. By the mid-1970s, Rockefeller had a major program in 
three areas of neuroscience, and the scientists in them made up one of the largest groups in 
the organization. These areas were (1) Molecular and Cellular Mechanisms, (2) 
Neurophysiology and Behavioral Physiology, and (3) Information Processing, 
Communication Behavior, Cognition, Memory, and Brain Function. Eventually, Nobel 
laureate Gerald Edelman of Rockefeller University would develop one of the most 
prominent theories in the broad field of neurobiology (Edelman, 1987, 1989, 1992; and 
Edelman and Tononi, 2000), and would be instrumental in arranging for the Neurosciences 
Institute to be located at Rockefeller University, where it remained until 1991. In addition, 
Edelman was instrumental in recruiting to the Rockefeller Torsten Wiesel, who had 
received the Nobel Prize for his work in the area of neurophysiology of vision. He became 
a Professor at Rockefeller in 1983 and President of the University in 1991. Edelman was 
also the key person involved in recruiting Paul Greengard, who in 2000 was awarded a 
Nobel Prize for his neuroscience research (interviews with Torsten Wiesel, Paul Greengard, 
and Gerald Edelman). From the time of Gasser to the present, these and numerous other 
distinguished scientists have placed Rockefeller in the vanguard of neuroscience.  
Research organizations may stay at the leading edge of science by bringing in senior 
scientists who have already been the pathbreakers in a field as well as by having 
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investigators already in the organization develop new frontiers. The capacity to do both is a 
result of past and present strategy choices and good leadership. This is most evident with 
regard to the role of biological chemistry at the Rockefeller. In this case, Emil Fischer’s 
school of organic chemistry was partially transplanted to the Institute in the early part of the 
century, and the transplantation subsequently branched in numerous directions, one of 
which was protein chemistry, giving rise to a number of major discoveries in the process. 
Indeed, Fischer’s prophecy in his 1902 Nobel lecture was very much realized at 
Rockefeller: “Since the proteins participate in one way or another in all chemical processes 
in the living organism, one may expect highly significant information for biological 
chemistry from the elucidation of their structures and their transformations” (Smith, 1979: 
116). 
At the Institute there were a number of scientists who had studied with Fischer and 
who, in turn, had inspired a number of luminaries of protein chemistry (e.g., John Northrop, 
Moses Kunitz, Wendell Stanley, Stanford Moore, William H. Stein, Lyman Craig, Alfred 
Mirsky). Loeb, while not trained as a chemist, also had a major influence in developing the 
tradition of protein chemistry at Rockefeller (Pauly, 1987: 152–153, 170–171). This lineage 
was responsible for the Rockefeller’s becoming a world-class center for major discoveries 
within the broad outlines of protein chemistry. In several respects, the critical period for the 
development of protein chemistry was between 1925 and 1960, when there was increasing 
evidence in both Europe and America that many important biological activities were due to 
specific proteins. While there was already vast information supporting this view, it was 
only during this period that protein chemistry was put on a firm experimental basis, largely 
as the result of the development of new methods and instruments that substantially 
increased the knowledge of the function and structure of proteins.  
One of the great protein chemists of the twentieth century, Max Bergmann, was 
appointed to Rockefeller in 1934. He had left Germany following the Nazis’ ascent to 
power. A former student of Emil Fischer, at the Rockefeller Bergmann attracted a group of 
able young scientists who would later develop into some of the leading protein chemists in 
the postwar world: William Stein, Stanford Moore, Joseph Fruton, Klaus Hoffman, Emil L. 
Smith, Paul Zamecnik—among others. Work on proteins at the Institute was largely 
suspended during World War II. However, when Bergmann died of cancer at the height of 
his career in 1944, the lab was left without a chief. Gasser demonstrated that he had an 
excellent ability not only to discern the direction in which science was moving but also to 
identify talent: He asked Moore and Stein—two relatively young scientists—to stay on at 
the Institute and gave them the freedom to do almost anything they pleased in the 
biochemical field. In 1949, they were appointed as Associate Members and they received 
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permanent appointments at the Institute in 1952. They won the Nobel Prize in Chemistry in 
1972 for their collaboration leading to the development of quantitative chromatographic 
methods for amino acid analysis, especially their automation techniques, which led to the 
entire sequence for ribonuclease A being described, the first complete description of the 
chemical structure of an enzyme.  
Gasser also demonstrated imaginative leadership with his support of other young 
scientists engaged in fundamentally new kinds of research. One example was his support of 
Lyman Craig—long associated with Walter Jacobs—who also worked independently in 
developing other techniques for purifying some proteins. For this work Craig was later 
awarded the Lasker Prize for Basic Biomedical Science.  
But nowhere did Gasser demonstrate better insight in judging the direction in which 
science might move than in his support of a group of young cell biologists. Albert Claude 
had arrived at the Rockefeller in 1929 and worked in the laboratory of James B. Murphy in 
an effort to purify and characterize the agent that caused a transmissible form of cancer in 
chickens, the Rous sarcoma virus. Working in the area of virology, Claude used a high-
speed centrifuge to spin fractionated cells infected with viruses in an effort to isolate and 
purify their agents. His investigations led to the determination that cells contained tiny 
bodies, which he labeled “microsomes.” The critical problem was to understand their 
structure and function. To address this problem, Claude used an electron microscope, a new 
laboratory tool. Under the pioneering influence of Claude’s younger colleague, Keith 
Porter, the Institute then led the way in the development of electron microscopy for the 
study of cell biology. Aside from Porter, Claude also had the assistance of a number of 
other young scientists—George Palade, Roland Hotchkiss, George Hogeboom, and Walter 
Schneider (Palade, 1971; interviews with Palade and Hotchkiss). 
It was the interdisciplinary environment of the Rockefeller Institute which 
facilitated Claude’s imaginative investigations. He brought to the study of cells deep 
insights from the fields of oncology, virology, biochemistry, histology, and cytology. His 
ability to internalize so much scientific diversity enhanced his ability to see things in 
fundamentally new ways, and so to lay the foundation for the development of cell biology 
at Rockefeller.  
Claude left the Institute in 1949 to return to his native Belgium, and Murphy—the 
head of the lab—retired in 1950. But Gasser’s keen eye for promising research, along with 
his willingness (as in the case of Stein and Moore) to keep a lab open when its head 
disappeared from the scene, set the stage for major new advances. Gasser chose to invest 
Institute resources in acquiring an electron microscope. Technically, Gasser became the 
head of the Porter-Palade group so that it might continue to function, though for several 
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years Porter actually provided the day-to-day leadership of the newly developed electron 
microscopy laboratory. It is no exaggeration to suggest that modern cell biology was born 
at the Rockefeller under the leadership of a diverse group of “junior” scientists (Palade, 
1971, 1977, 1998). 
Without the nurturing role of Gasser in deviating from the precedent of closing 
down laboratories when their heads departed, these developments would not have occurred. 
Significantly, it was Gasser’s support for the development of new technologies needed for 
new fields of research which facilitated Rockefeller’s becoming one of the world’s leading 
centers for protein chemistry and cell biology (interview with Palade). 
But perhaps the single most notable achievement in the entire history of the 
Rockefeller was the paper by Oswald Avery and his younger colleagues Colin MacLeod 
and Maclyn McCarty in 1944, which offered evidence that genetic specificity is embedded 
in the chemical structure of DNA (McCarty, 1985; Lederberg, 1985). The story of this 
work, which had little to do with Gasser’s leadership, has been recounted many times, and 
there is no need to go into great detail about it here. However, it is worthwhile to note 
certain aspects of the process of this discovery in order to illustrate how the structure and 
culture of Rockefeller facilitated scientific creativity.  
Today, there is universal recognition that the paper from Avery’s group represents 
one of the most important discoveries in the history of the biomedical science. Nobel 
laureate Joshua Lederberg has observed that between twenty and twenty-five Nobel Prizes 
were subsequently awarded for research dependent on the 1944 paper. Similarly, Peter 
Medawar, the Nobel laureate immunologist, called the discovery “the most interesting and 
portentous biological experiment of the twentieth century” (Lederberg, n.d.; Bearn, 1996: 
550–554; Rockefeller University, 1993: 2).  
From the viewpoint of my research, there are several intriguing problems related to 
the Avery paper. Since the Rockefeller Institute was the dominant center of the Protein 
Central Dogma, how was it that the challenge to this paradigm came from within the 
Institute and was made by a bacteriologist and physician, Avery, who lacked formal 
training in chemistry and genetics? Could this discovery have been made anywhere else at 
approximately the same time? 
As a trained physician, Avery spent much of his career concerned with 
understanding pneumonia and attempting to devise strategies for either treating or 
preventing the disease. It is no exaggeration to say that by 1940 he was one of the world’s 
foremost authorities—if not the foremost authority—on various types of pneumococcus. 
Over the years, his research had shifted from an interest in the development of an effective 
serum for the treatment of pneumonia to an immunochemical understanding of the 
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chemical basis of the biological specificity of different types of pneumonia. For more than 
two decades, a dialectic was operating in Avery’s mind: the applied scientist’s concern with 
treating and preventing pneumonia, and a basic scientist’s concern with the underlying 
chemical and biological processes. It was the tension between these two forms of inquiry 
and the effort to integrate them which was the key to Avery’s scientific creativity. In our 
own day, as those trained as either basic scientists or physicians tend to drift further and 
further apart, the story of how Avery integrated the concerns of both the clinician and the 
basic scientist needs to be carefully noted.  
Avery spent his entire Rockefeller career in the pneumonia section of the Hospital 
Department. While the leading investigators in the Hospital (e.g., Cole, Cohn, Dochez, 
Horsfall, Rivers, Van Slyke) were clearly distinguished investigators by national standards, 
there was a tendency after World War I among many in the Laboratory Department to 
perceive the Hospital investigators as applied investigators and therefore somewhat 
inferior. Avery was very much aware that while he was highly specialized and 
knowledgeable about pneumonia, he was an outsider as far as fundamental knowledge of 
physics, chemistry, and biology was concerned. But like all his colleagues in the Hospital 
Department, he was obsessed with learning, and he constantly tried to absorb basic 
knowledge from his Laboratory colleagues in an effort to expand the scope of his 
specialty—pneumonia. 
During the 1930s, Avery had lunch at the tables for which the Institute was famous 
with such distinguished organic and biological chemists as Phoebus Levene, Karl 
Landsteiner, Donald Van Slyke, Alfred Mirsky, Max Bergmann and his brilliant young 
associates William Stein, Stanford Moore, Joseph Fruton, Emil L. Smith, and Paul 
Zamecnik. Moreover, he had a high degree of familiarity with the work of John Northrop 
and Wendell Stanley, who would be awarded Nobel Prizes in 1946. Never has one 
organization had such a stellar collection of biological chemists all in one place and all 
clearly working at the frontiers of science. It is no wonder that on two separate occasions 
Linus Pauling, one of the century’s greatest chemists and at the other end of the continent, 
collaborated with members of this group (e.g., Landsteiner and Mirsky). For Avery, as a 
non-chemist, the ability to lunch on a daily basis with such a collection of scientists was 
exhilarating, but at the same time somewhat intimidating.  
Once he set out to identify the substance responsible for transforming one type of 
pneumococcus to another, Avery was determined to seek information from any available 
source. He frequently sought the counsel of the great scientists at the Rockefeller. 
Revealing his ignorance about the latest methods in chemical analysis that had been 
developed at Rockefeller and elsewhere, he was not shy in approaching his scientific 
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colleagues in the privacy of their labs. Had he been a microbiologist in a large university in 
America, he would never have had the opportunity to learn over the lunch table so much 
about the recent advances which had taken place in protein chemistry during the previous 
twenty years.  
While Avery recognized the need to borrow from other fields in order to address his 
particular research problems, he generally preferred to work with young scientists who had 
been trained as physicians rather than as basic scientists. However, on several occasions he 
did work with young basic scientists, including Michael Heidelberg and René Dubos, with 
notable success, and those collaborations helped to prepare the way for his 1944 paper. It is 
doubtful whether Avery could have acquired the same degree of scientific diversity in any 
other organizational environment to do the experiments which resulted in his 1944 paper 
(Amsterdamska, 1993: 25–27; Dubos, 1976; Olby, 1974: 183–185).  
There is another aspect of work on the 1944 paper which deserves attention, a 
consideration which reveals much about distinguished research organizations. Major 
discoveries are often rooted in specific local cultures, and that was indeed the case with 
Avery and the Rockefeller institution. Jacques Loeb—one of the most influential scientists 
in the history of the Rockefeller—played an important role in establishing a physico-
chemical viewpoint on biological processes, a perspective which early became dominant at 
the Institute. As Dubos (1976: 46) has observed, because of Loeb’s influence “ways of 
thinking about life ... that do not involve a physico-chemical approach have never found a 
congenial home within the walls of the Rockefeller Institute.” Significantly, protein chemist 
John Northrop, whose work had aided Avery, had worked under Loeb. Indeed, Loeb’s 
interest in protein chemistry had a profound influence on Northrop’s decision to consider 
the protein nature of enzymes, which culminated in his Nobel Prize. Northrop, in turn, had 
a profound influence on Wendell Stanley, Moses Kunitz, and other distinguished 
enzymologists and virologists at the Princeton Laboratory of the Institute. And it was the 
enzymology work of the Princeton group—operating as a legacy of Loeb—that led Avery 
to develop his most convincing evidence that the pneumococcal transforming substance 
contained DNA as an essential factor of the genetic determinant (Cohen, 1979). 
Anticipating modern genetics, as early as 1912 Loeb had written that one of the most 
important tasks for the biological sciences was to determine the chemical substances in the 
chromosomes responsible for heredity. More than one observer has emphasized the 
importance of Loeb in developing a tradition of a physico-chemical viewpoint of biology 
which ran through Simon Flexner to John Northrop and Wendell Stanley to Avery and 
ultimately to Jim Watson’s decision to work on the structure of DNA (Fuerst, 1982; Wyatt, 
1972; Rasmussen and Tilman, 1998; Loeb, 1964; Watson, 1968: 29–30). 
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In his years at the Institute, Gasser had the assistance of a number of the country’s 
leading scientists on the Board of Scientific Directors: Detlev Bronk, who during his tenure 
became President of Johns Hopkins University, President of the National Academy of 
Sciences, and Chairman of the Board of the National Science Foundation; James B. Conant, 
President of Harvard University; Vincent du Vigneaud of Cornell University (a future 
Nobel laureate); Warfield Longcope of Johns Hopkins University, one of the nation’s 
leading professors of medicine; and Nobel laureate George H. Whipple of Rochester 
University. With their guidance and the participation of the scientific staff—some of them 
mentioned above—new pathways were opened not only in such broad areas as protein 
chemistry and cell biology, but also in the mechanisms of heredity and virology.  
During the depression and World War II, the Board of Trustees and the Board of 
Scientific Advisors were troubled by the declining rate of income from the Institute’s 
investments and by rising expenditures. Partly for this reason, the Trustees decided in 1947 
to close the Institute’s research site in Princeton, New Jersey, facilities established 
approximately three decades earlier. In addition to financial considerations, the two 
governance boards were very much concerned about the physical separation of the two 
facilities. The decision was very controversial, for two members of the Princeton staff 
(Northrop and Stanley) had recently been awarded the Nobel Prize in Chemistry. With the 
closure of the Princeton department some Princeton staff returned to New York City, and 
others parted from the Rockefeller Institute. 
 
 
THE PRESIDENCY OF DETLEV BRONK 
 
The Institute had never been content to rest on its laurels, and had continuously 
been willing to make serious reassessments of its performance. Accordingly, the Trustees—
in anticipation of Gasser’s retirement—appointed a committee in the early 1950s to make 
recommendations about the Institute’s future. Given that by the early 1950s no research 
organization in the world had made so many major discoveries in biomedical science 
during the twentieth century, it is remarkable that the committee was prepared to look at a 
series of radical options for the future. The committee seriously considered whether the 
Institute should be closed down and its assets distributed to other research organizations, 
whether it should move from New York to a less costly environment, or whether it should 
merge with an existing university. 
By the early 1950s, it was clear to the Board of Trustees that the Rockefeller 
Institute had more than achieved its original purpose of providing a model of a high quality 
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research organization in biomedical science, one which would set the standard of 
excellence in biomedical science. Partly because of the existence of the Rockefeller 
Institute, there were now numerous research organizations making important discoveries 
and training very good scientists. By 1953, more than 200 former members of the scientific 
staff held the rank of full professor (or the equivalent) in research centers throughout the 
country. Thus, if the Institute had attained its goal of helping to develop centers of 
biomedical research excellence in the country, why should its existence be continued? 
Perhaps Rockefeller wealth should be used for some other societal purpose not yet being 
addressed? 
The committee consulted with a number of leading scientists throughout the 
country. Detlev Bronk, one of the most influential members of the committee, was 
adamantly opposed to closing the Institute. Recognizing that the Institute had achieved its 
initial goals, Bronk took the view that the Institute should revise its goals and purposes. In 
the future, it should not only be a center of research excellence, but should also have as a 
major goal the providing of graduate education for the future scientific leaders of the 
country. Because it would be a new kind of training center, the Rockefeller organization 
would continue to do something distinctively different from all other educational centers in 
America.  
Impressed with Bronk’s ideals, the Trustees prevailed upon him to become Gasser’s 
successor. Thus, in 1953, the Trustees voted to change the Institute into a graduate 
university with the authority to grant the degree of Doctor of Philosophy and Doctor of 
Medical Science. The Board of Scientific Directors was abolished and the Board of 
Trustees became the sole governing authority of the organization. The Rockefeller Institute 
became a small university, the only graduate university in the United States. However, it 
was not until 1965 that the name was changed from Rockefeller Institute for Medical 
Research to Rockefeller University. 
Bronk, who served as President from 1953 until 1968, was very troubled that the 
nation’s leading centers of training were producing such highly specialized people, whom 
he pejoratively characterized as technicians. In contrast, he wanted the Rockefeller to 
produce scientists who had broad knowledge in a variety of fields. He recognized that 
scientific excellence required a mastery of subject, but thought it was important that 
scientists understand how their own research was intricately related to other fields of 
science. A recurring theme in his public speeches was the desirability of the unity of 
knowledge, and for him the ideal university was one in which there would be intense and 
frequent interaction among scientists from diverse fields. Ideally, each scientist would have 
a broad competence in many areas of science. Moreover, Bronk was very humanistically 
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oriented, and frequently spoke of the importance of scientists’ understanding how they 
were inextricably connected to the past, present, and future of their society. For Bronk, the 
importance of scientific research was to be measured by its larger humanitarian 
contributions to society. The transformation which he proposed for the Rockefeller 
organization was that it would be a training ground for the future leaders of science, 
scientists who would aspire to break down artificially segregated areas of knowledge and to 
struggle for the realization of the unity of knowledge for the benefit of society (Chance, 
1978; Adrian, 1976; Brink, 1976, 1979). From time to time, Bronk would preach to the 
Board of Trustees about the kind of university he had in mind, as he did at the Trustees’ 
meeting of May 22, 1961: 
It is unwholesome, and indeed dangerous for the future 
welfare of mankind, for scientists to live and work, to study 
and teach, in an environment in which they are not in close 
contact with creative, critical scholars in the humanities and 
arts. Such associations are a valuable quality of a university. 
Lack of such contact with those who help determine the 
future of civilization makes specialized research institutes 
barren intellectual environments.  
But how might a small university attain such goals? Paradoxically, a small 
university such as Rockefeller has more potential to produce broadly trained scientists than 
larger research universities which teach almost everything. Bronk believed that it was 
inappropriate to include all fields of science in the research program. In the largest research 
universities with their increasing fragmentation and specialization, such a goal had become 
increasingly difficult to achieve. When universities attempt to encompass all fields of 
science, some areas are invariably mediocre, and when mediocrity develops in some fields, 
it leads to mediocrity elsewhere. Because of the small size of the Rockefeller University, 
Bronk recognized that it could not offer programs in the humanities. As a result, early in his 
presidency the university offered each student a fund of $1,000, to take advantage of the 
rich cultural offerings in New York (such as concerts, opera, theater, ballet, museums, or 
galleries). Moreover, he arranged for humanists and social scientists to present frequent 
public lectures at the University and for concerts to be held in its facilities. 
Because it was not feasible to encompass all specialized fields of science, the 
university would focus on the “most significant, most fundamental and most broadly 
relevant areas of mathematics, physics, chemistry, and biology.” Since the university was 
organized around individuals rather than around departments, its structure should 
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encourage cooperation in teaching and research. Accordingly, in recruiting faculty to the 
university, emphasis was placed on the choice of people who had broad interests and who 
by inclination enjoyed collaboration with others in diverse fields of science. However, the 
emphasis on breadth of scholarly interests and interdisciplinary cooperation did not mean 
that certain individuals or groups would be recruited simply to provide service for more 
fundamental areas of science. Indeed, the philosophy at Rockefeller was that all scientists 
and groups were encouraged to be autonomous, with their own identity and dignity. 
The program which Bronk espoused had implications for the growth of the 
university, however. When Bronk became President in 1953, there were 21 Members, 
whereas at the end of his tenure as President, there were 51 Professors. In the same period, 
there was a tripling in the size of the scientific staff from 99 to 303.8 Whereas in 1953, there 
were biological scientists, medical doctors, biophysicists, and physical chemists, the faculty 
was quickly expanded to include scientists in psychology and animal behavior, physics, 
mathematics, and philosophy. Moreover, the fields of biology, chemistry, and biophysics 
were extended. Within three years Rockefeller appointed as professors several scientists 
who had either already been awarded or would later be awarded Nobel Prizes: Keffer 
Hartline from Johns Hopkins, Fritz Lippman from the Harvard Medical School, and 
Edward Tatum from Stanford. Other distinguished, senior faculty appointed during the 
Bronk years were the philosopher Ludwig Edelstein, the biologist Paul Weiss, the 
mathematician Marc Kac, physicists George Uhlenbeck and Abraham Pais, behavioral 
scientists Carl Pfaffmann, Neal Miller, and Floyd Ratliff, the geneticist Theodosius 
Dobzhansky, the cell biologist Christian de Duve, and the chemist Theodore Shedlovsky. 
Bronk also arranged for a number of the world’s leading scientists to spend a week or two, 
over a period of several years, with the students: Lord Adrian of Cambridge, Isidor Rabi of 
Columbia, David Goddard of Pennsylvania, Ragnar Granit of Stockholm, John Kirkwood 
of Yale, Kaj Ulrik Linderstrom-Lang of Copenhagen, Louis Marie Monnier of Paris, Alex 
von Muralt of Bern. By the end of Bronk’s term as President, Rockefeller University had 
one of the most distinguished collections of biomedical scientists in the world.  
For Bronk, the University was to be a genuine community of scholars with graduate 
students, postdocs, and faculty having intense and frequent interaction—all engaged in 
learning from one another. An important key to such a university was the selection of 
students, and he frequently argued that it was important that students be selected with the 
same care as the faculty. Hence, during his years as President, Bronk personally 
                                                 
8 Academic Affairs, Bronk Papers, Record Group 303, Box 7, File 9, RAC; Report of Six Faculty 
Committees, September 9, 1968, Bronk Papers, Record Group 303, Box 17, File 4, RAC. 
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interviewed most of the students before they were admitted. The only students selected for 
admission were those whose commitment to advanced study and research was believed to 
be equal to that of the faculty. All students were considered to be intellectually mature, 
highly motivated, and capable of self-study. As a result, there was to be no core curriculum. 
Each student was to have his/her own program of study based primarily on learning from 
advanced textbooks, professional journals, tutorials and seminars on special subjects, and 
work in the labs of some of the world’s most distinguished and experienced scientists. In a 
sense, there was a separate curriculum for each student. Even though Rockefeller 
technically had been transformed into a university, it remained more of an institute than a 
research university as normally known in American society. Rarely would more than 
twenty-five graduate students be admitted a year, and by 1966 there were only 128 students 
(Brink, 1976; Lyon, 1964). Because there were so few students relative to the number of 
faculty, close associations developed among students and faculty (Brink, 1979: 67; 
interviews with Hotchkiss, Gally, Edelman, Zinder).  
Normally, admitted students had completed an undergraduate baccalaureate or held 
a Doctor of Medicine degree. Students were usually candidates for the degree of Doctor of 
Philosophy, but those who were Doctors of Medicine could pursue a degree of Doctor of 
Medical Science. Thus, one of the major goals in moving from an institute to a university 
was to prepare young people to be scientific leaders of the nation—as David Rockefeller 
expressed it, “a reaffirmation and an expansion of prior objectives, a reaching out to new 
opportunities for the pursuit of excellence” (Rockefeller, 1976: 88; interview with 
Rockefeller). 
During the years of Bronk’s presidency and ever since, the Rockefeller organization 
has been confronted with somewhat paradoxical goals. It aspires to have considerable 
breadth in its scientific interests, yet is determined to remain small and to permit each lab to 
be autonomous. It has been difficult to maintain strength in chemistry, physics, 
mathematics, and different fields of biology, and at the same time to promote 
interdisciplinary cooperation. For many years, the University attempted to address this 
paradox by promoting the unity of science through the interpretation of biological 
phenomena in physical and chemical terms. Perhaps unsurprisingly, a number of scientists 
who were recruited to Rockefeller as organic or physical chemists over time became 
biochemists. Some physicists became biophysicists, and some mathematicians emigrated to 
other fields as a result of their interests in computer science and various technologies. Thus, 
at the Rockefeller there has long been a strategy of recruiting scientists who have broad 
interests and who by temperament have been eager to collaborate with and learn from those 
in other fields. Because of its small size, the Rockefeller has generally been reluctant to 
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recruit those who by temperament prefer to work in isolation—though over time there have 
been exceptions. 
Another aspect of the continuity between the Bronk years and the culture of 
excellence institutionalized during the Flexner years was the historical emphasis on 
providing services for the scientific staff: the design and construction of instruments, 
illustration services, glass blowing, a spectroscope laboratory, etc. To keep these and other 
services at a high level of excellence, over the years the organization has recruited an 
extraordinary staff trained in the techniques of mechanical, electrical, and chemical 
engineering.9 Having state-of-the-art support services has been important in keeping the 
Rockefeller at the cutting edges of multiple fields of science. 
Accompanying the expansion of faculty during the Bronk years was a building 
program that reshaped the physical setting of the University. This included a residence for 
graduate students and a building with two wings: the Abby Aldrich Rockefeller Hall 
(containing a dining room, lounges, library, and accommodations for visiting scholars) and 
the Alfred H. Caspary Hall (with administration offices). Connected to Caspary Hall was a 
new auditorium. A modern nine-story laboratory and several smaller buildings were also 
constructed (From Institute to University, 1985: 14). Bronk’s aesthetic aspirations for the 
University were revealed by his arranging for one of the world’s leading landscape 
architects, Daniel Urban Kiley, to design the University’s grounds in the late 1950s. The 
result was the development of some of the most beautiful grounds in the city. 
Bronk was a dreamer, a person whose ambitions for the University were virtually 
without limit. Hence, it is not surprising that it soon became obvious that the University 
could not survive primarily on its endowment, as in the past. Once extramural funding from 
the National Institutes of Health became available, the Rockefeller organization began to 
turn to the federal government for research funding. This marked a critical turning point in 
the history of the organization: Labs began to grow in size, turned somewhat inward, and 
became somewhat more independent from the rest of the University. No longer did 
everyone have lunch together. There were too many senior scientists and students for the 
early twentieth-century type of communication and integration to exist. Many labs began to 
have their own journal clubs, and attendance at the weekly Friday afternoon scientific 
presentations for the entire organization dropped off dramatically. There was no longer the 
same degree of horizontal communication across labs as during the first half of the century. 
Of course, Rockefeller University was still quite small relative to most American research 
universities, but as size increased, the degree of integration and communication among the 
                                                 
9 Memo of September 18, 1968, Bronk Papers, Record Group 303, Box 17, File 4, RAC. 
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scientific staff diminished (interviews with Seitz, Lederberg, McCarty, Edelman, 
Hotchkiss, Zinder, Archibald). 
 
 
THE PRESIDENCIES OF FRED SEITZ, JOSHUA LEDERBERG, AND DAVID 
BALTIMORE 
 
It is not unusual that an organization which undergoes rapid expansion and 
reorganization under one leader later finds that the rate of change is not sustainable, and 
therefore the next leader faces a period of major readjustment and stabilization. This is 
precisely what happened under the University’s next president, Fred Seitz (1968–1978), a 
physicist. Like Bronk, he had been President of the National Academy of Sciences.  
With hindsight, it is obvious that the University had been extravagant in its 
expenditures during the Bronk years. After Seitz became President, the economic 
environment of the University quickly changed. By 1970 the University, like many others 
throughout the country, found itself confronting serious financial problems, exacerbated by 
inflation—rising salaries as well as construction and energy issues. There were cuts in some 
federal grants, causing the University to draw money from its endowment to support 
programs to which it was committed. Moreover, the recession that began in 1968 led to a 
drop in income from the endowment. Because non-academic pay scales had fallen below 
city standards during the Bronk years, Seitz and his staff now had to address this problem 
as well. For the first time in its history, the organization was confronted with not only a 
deficit, but a mounting one. This was the shape of things as Seitz completed his first year as 
President. As during the depression of the 1930s, the University was forced to undertake a 
serious assessment of its operations, the result of which was the recognition that the 
institution could not sustain the rate of growth of the Bronk years. Overall, the 1970s and 
1980s were difficult years. For financial reasons, if for no other, Seitz had no alternative but 
to undo some of the decisions of his predecessor. In contrast to years of fanfare and 
ceremony under the presidency of Bronk, the tone during that of Seitz was more restrained, 
due to the financial difficulties which the University faced. Recruiting continued, but less 
aggressively. On-site staff were carefully reviewed, and laboratories were warned that long-
term prospects for funding their researchers were very limited for financial reasons 
(interviews with Seitz, Nichols, McCarty, Lyons). 
Even so, the 1970s and the 1980s were decades of outstanding achievement and 
recognition. In 1969, Bruce Merrifield was awarded the Lasker Prize for Basic Biomedical 
Research for his work in developing a method for the synthesis of polypeptides and 
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proteins, and in 1984 the Nobel Prize in Chemistry for the same line of work. In 1972, 
Gerald Edelman was awarded the Nobel Prize in Physiology or Medicine (shared with 
Rodney Porter of Oxford University), while William Stein and Stanford Moore (with 
Christian Anfinsen of the National Institutes of Health) received the Nobel Prize in 
Chemistry (Edelman, 1994). Two years later (1974) Albert Claude, George Palade, and 
Christian de Duve shared the Nobel Prize in Physiology or Medicine for work they had 
conducted at Rockefeller, and two years earlier (1970) Keith Porter and George Palade had 
shared the Louisa Gross Horwitz Prize for their investigations involving electron 
microscopy of biological materials. 
The University Trustees became increasingly concerned about their dependency on 
federal funding for research. Cuts at the federal level could imperil ongoing research, just 
as, to the contrary, a War on Cancer could cause coffers to open. Fearful that in the longer 
term, federal funding would prove unstable and would reduce the University’s autonomy 
and flexibility, the Trustees instituted campaigns to raise funding from the private sector 
(such as individuals, foundations, and business firms). The Trustees intended that federal 
grant money would provide about half of the University budget, and the other half of the 
budget would be covered by private fund-raising and income from the endowment. Private 
sector funding was absolutely necessary if the University was to remain at the frontiers of 
biomedical science, and especially to expand its research program in cell biology and 
molecular biology.  
By the end of the Bronk years, the Trustees had approved the creation of a 
University Senate and an Academic Council, which was the Executive Committee of the 
Senate. As a result, a number of senior faculty increasingly insisted on being involved in 
decision-making in university affairs, very much in contrast to the years when the 
organization was a relatively small institute. During the Flexner and Gasser years, even 
senior Members rarely knew what major decisions were being made by the Director and the 
two Boards. Indeed, during the Gasser years, the Institute offered senior positions to Linus 
Pauling, Carl Cori, Vincent du Vigneaud, and Francis Schmitt—all of whom declined—but 
the author of this paper has been unable to find any evidence that any Member of the 
Institute’s staff was ever informed of these efforts.10 
During the Bronk years, the scientific staff had continued to be relatively 
uninvolved in the governance of the Rockefeller. But once the University experienced the 
financial deficits of the 1970s and 1980s and difficult choices had to be made about how to 
                                                 
10 Summary of W. F. Loomis interview with Herbert Gasser. Rockefeller Family Papers, Record Group 3, 
Box 51, Folder 534, p. 26, RAC. 
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reduce the deficits, the faculty attempted to become much more involved in the governance 
of the University. Whereas there had been virtually no discussion among the scientific staff 
in the early 1950s as to whether graduate students should be trained at the Rockefeller, 
during the Seitz years the faculty began to discuss what proportion of funds should be 
devoted to teaching as distinct from research, the degree to which heads of laboratories 
would have complete autonomy in appointing scientists in their own labs, how many 
Rockefeller-funded scientists might be in a single lab, and how decisions would be made 
about the appointment and promotion of laboratory staff. Clearly, changes in the economic 
environment in which the University was embedded had suddenly made the governance of 
the University much more complex than had been the case during the Bronk years, when 
the American economy was much more expansive. In sum, the process of institutionalizing 
a new mode of decision-making in an era of fiscal constraints created stress within the 
organization. Fortunately for the University, Seitz was a very stable and unflappable 
administrator, who realized that if the University was to continue being a distinguished 
scientific center, long-term financial planning would have to be integrated into the day-to-
day management of science. As research became much more expensive and the structure of 
research organizations more complex, many more factors entered into the management of 
an organization. In short, the complex demands of administering the organization between 
1970 and 1990 made necessary a marked departure from the more personalistic style of 
management which had existed prior to Seitz’s presidency. 
Meantime, Seitz and his successor, Nobel laureate Joshua Lederberg (1978–1990), 
were also very attentive to the infrastructure of the university, keeping it as a world-class 
center in instrumentation design and construction, and attempting to add new laboratory 
space (From Institute to University, 1985: 18). During the Seitz presidency, Hidesaburo 
Hanafusa, James Darnell, and several other senior faculty were recruited, but most efforts 
to add other senior staff came to nil. Even so, during the early years of Lederberg’s 
presidency the University continued its efforts to make distinguished appointments, 
appointments which resulted in great distinction for the University: Jan Breslow, Paul 
Greengard, Torsten Wiesel being the most high-profile (interviews with Breslow, 
Greengard, Wiesel, Nichols, Seitz, Lyons, J. Darnell, Hanafusa).  
Throughout the presidency of Lederberg, the University’s financial condition 
continued to be constrained by the poor performance of the American economy. Believing 
in the desirability of Rockefeller University remaining small, Lederberg reduced some 
layers of administration and attempted to make himself more directly available to faculty. 
Many of his plans—whether very general or more programmatic (e.g., parasitology, 
toxicology)—were hard to realize without more discretionary funds. A great deal of 
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energy—administrative, trustee, and faculty—was invested simply in addressing fiscal 
problems of daily living. Issues such as fund-raising and problems attendant upon life in the 
city (e.g., lack of affordable housing for both junior and senior faculty) were never-ending.  
Throughout the century, the two John D. Rockefellers and David Rockefeller were 
always available to lend support to the Rockefeller during times of stress. David 
Rockefeller joined the Rockefeller Institute Board of Trustees in 1940 and served for more 
than 55 years. In 1950, he succeeded his father as President of the Board. It is difficult to 
imagine how the Rockefeller could have remained a center of scientific excellence without 
his counsel, his financial assistance, and his ability to be a bridge between the University 
and other sectors of American society. Rockefeller’s political connections with local, state, 
and national governments and with elites in many sectors of American society were very 
valuable assets for the University. David Rockefeller’s associates and members of his 
family report that his involvement with the University’s affairs was the most important 
commitment of his public life, even more important than his role as Chairman of the Board 
of the Chase Manhattan Bank and his other activities involving local, national, and 
international affairs. For almost forty years, he hardly ever missed a meeting of the 
University’s Board of Trustees, and was generally available to University administrators 
and scientists who wanted to consult with him about University affairs (interviews with 
Goodwin, Pillsbury, Lederberg, Nichols, Bowen, Rockefeller, Edelman, Seitz, Wiesel). 
Several perspectives concerning the behavior of organizations need to be kept in 
mind in order to understand some of the internal turmoil which occurred at the Rockefeller 
between 1989 and 1991. By the late 1980s, there was an increased perception both within 
and outside of Rockefeller University that it was not performing as well as it had some 
decades earlier. Changes in the environment—especially the availability of funding from 
the National Institutes of Health (NIH)—had a major effect on the university. The center of 
gravity of basic science research had shifted westward, partly as a function of the existence 
of jet aircraft. Increasing numbers of scientists were willing to have careers on the West 
Coast—in Berkeley, Seattle, Los Angeles, San Diego, and elsewhere. And as the cost of 
living in the New York environment escalated, it became increasingly difficult for the 
Rockefeller to recruit scientists of their first choice, a constraint that had been quite rare in 
earlier years (interviews with J. Darnell, Seitz, Lederberg, Zinder, Nichols). 
In the early part of the century, ambitious young biomedical scientists had been 
eager to spend a few years at Rockefeller Institute. By the latter part of the century, there 
were many centers of excellence throughout American society, and the best of the nation’s 
young scientists were increasingly unwilling to go to the Rockefeller, for there most young 
scientists were not able to be heads of their own labs until they attained the rank of full 
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professor. By the late 1980s, it was well known that many of the nation’s best biomedical 
scientists had their own labs when they were quite young (e.g., Joshua Lederberg and 
Howard Temin at Wisconsin, Paul Berg and Dale Kaiser at Stanford, Jim Watson and 
Walter Gilbert at Harvard, Mike Bishop and Harold Varmus at the University of California, 
San Francisco). With numerous research centers throughout the country, most good young 
scientists increasingly expected to have more autonomy and their own laboratories before 
becoming senior professors. This was a problem which was widely discussed within the 
Rockefeller, but by the late 1980s, more often than not, young scientists were still not 
becoming heads of labs. As senior scientists retired, it became increasingly difficult to 
recruit distinguished replacements. At the same time that these problems arose, the 
Rockefeller, like most of the nation’s leading research universities, was required to institute 
salary and wage freezes in response to the poor performance of the American economy 
(interviews with Temin, Lederberg, Kaiser, Gilbert, Bishop, Varmus, Watson, Baltimore, 
Zinder). 
Apart from the fiscal problems and the junior staff problems, the University faced 
the persisting tasks of developing new labs and renovating old ones—a constant at all 
serious research organizations. With changes occurring at an ever-increasing rate in the 
larger world of science, there were unrelenting pressures to recruit new faculty in molecular 
biology, neurobiology, and cancer research, as well as in other areas. By 1990, however, 
the University had recruited only one senior scientist from the outside in the previous five 
years. In 1990 the average age of the tenured faculty was fifty-eight, meaning that within 
another decade, a number of distinguished faculty would retire.  
In the midst of these changes in the larger environment, David Baltimore of MIT, a 
Nobel laureate, became President of Rockefeller in July 1990. A former graduate student at 
Rockefeller, Baltimore was one of the nation’s most productive scientists and was widely 
perceived to have been a very successful administrator of the Whitehead Institute for 
Biomedical Research, an affiliate of MIT. His appointment was strongly opposed by a 
sizable minority of the Rockefeller faculty, primarily because of the complex and 
unresolved investigations of a scientific paper which he and several of his MIT 
collaborators had published in Cell in 1986 (Boston Globe, October 5, 1989: 43). There 
were allegations that some of the experiments in the paper were misreported by the senior 
author, Thereza Imanishi-Kari. While there were no suggestions that Baltimore personally 
misrepresented the data in the paper, he was widely criticized for failure to conduct a 
proper investigation into the allegations about the paper and for defending the “flaws” in 
the paper too long and too vigorously. Because of this cloud over Baltimore, his tenure as 
President of Rockefeller became very controversial (Kevles, 1998, 1999). His most vocal 
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critics—both inside and outside of the University—charged that he had been 
extraordinarily arrogant in his handling of many of the issues related to the disputed paper 
(interviews with Zinder, Blöbel, J. Darnell). 
By the time Baltimore arrived in the summer of 1990, the University had made 
efforts to address some of its outstanding problems. A new laboratory building was under 
construction, and in 1989 several junior faculty had been appointed as heads of 
laboratories. Still, a number of procedures for dealing with the retention, dismissal, and 
promotion of junior faculty had not been resolved, and the University’s budget was 
seriously unbalanced, with a deficit of $12.3 million during Baltimore’s first year. 
Baltimore immediately initiated a $250 million fund-raising drive and instituted a 
wage freeze. At the same time, he established a number of search committees to recruit 
junior and senior faculty, and proposed major changes with regard to the status of junior 
faculty. In short, although Baltimore addressed problems already on the University’s 
agenda, he was clearly a catalyst, dramatizing the University’s problems and acting 
decisively with regard to some of them. 
This was not an auspicious time. With so many major issues crowding his agenda, it 
was especially difficult for Baltimore, as a new President, to establish his authority and 
legitimacy. He was attempting not only to manage the University but at the same time to 
operate his laboratory. Relocating and setting up his lab was quite time-consuming. The 
tensions created by the 1986 Cell paper continued, casting a pall over his Presidency. 
Within the University, turmoil over the paper was compounded by the fact that a few of the 
senior faculty had known Baltimore since his graduate student days at Rockefeller, and 
intensely disliked him. Some felt that he had a long history of being arrogant and recalled 
that as a student, he was frequently referred to as “Little Lord Baltimore” (interviews with 
Norton Zinder). Moreover, some senior faculty resented the way that Baltimore arrived as 
President: They felt that he viewed himself as the man on horseback who was coming to 
save the University from a group of entrenched oligarchs. Some faculty were embittered by 
rumors heard around the country that he had long badmouthed the University. The 
sentiment of one senior faculty member captured the views of many others. “To portray this 
faculty as a bunch of old dying swans who have lost touch with modern biology is complete 
and utter nonsense” (Science, December 13, 1991. 254: 1577). 
Almost everything Baltimore proposed quickly became controversial in one quarter 
or another. Although the senior faculty were essentially in agreement about the desirability 
of changing the role of the junior faculty with regard to heading labs (as indicated by the 
virtually unanimous approval of the Academic Senate in the fall of 1990 for Baltimore’s 
proposals regarding junior faculty), controversy continued about even this issue. Despite 
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the agreement on the principle that some scientists who were not professors might head 
labs, issues about which junior faculty would head labs were unresolved. In May 1991, five 
assistant and associate professors were selected to be heads of labs, bringing to sixteen the 
number of non-tenured heads of laboratories (News and Notes, May 17, 1991). As 
Baltimore rewarded some junior faculty with their own labs, cleavages emerged within the 
junior ranks. It appeared as though a two-tiered system of junior faculty was emerging. 
Some junior faculty received internal promotions, while others realized that their long-term 
chances of heading labs were no better than before Baltimore’s arrival. 
The issue of the Cell paper, too, simply would not disappear. In early 1991, there 
were leaks in the press to the effect that the U.S. Secret Service had uncovered evidence of 
fraud by Imanishi-Kari. In the spring, Baltimore’s public comments about the Cell paper 
led to an intensification of criticism of him and the University, both in the press and among 
some of the nation’s most respected scientists. As these criticisms reverberated within the 
University, Baltimore turned to junior faculty for support, leading to criticism that he “was 
using the junior faculty at some risk to their own careers” (New York Times, December 4, 
1991, B11; interviews with De Lange, Friedman, J. Darnell, Kuryian). 
Finally, in the fall of 1991, in the midst of this turmoil, the overwhelming sentiment 
of the senior faculty was conveyed to the Trustees that Baltimore was incapable of being an 
effective President, and shortly thereafter he resigned (Science, December 13, 1991, 254: 
1578). With hindsight it is obvious that the Baltimore Presidency was unfortunate for the 
University as well as for Baltimore himself. In July 1996, a three-person board appointed 
by the Department of Health and Human Services concluded that the “preponderance of 
evidence” indicated that the allegations about misconduct in producing the data in the Cell 
paper could not be proven (Kevles, 1998). 
There was a great deal of ill-chosen rhetoric on the part of both supporters and 
critics of Baltimore during the affair. Some of the rhetoric of Baltimore and his supporters 
early on suggested that the Rockefeller faculty was depleted and that the quality of science 
was no longer distinguished. The validity of these claims requires some perspective. It is 
true that there was a time when it was believed at Rockefeller that anyone receiving a 
permanent appointment at the organization should do work of a caliber to make the person 
a serious contender for a Nobel Prize. But with increases in size and the emergence of 
several dozen major centers of biomedical scientific research throughout the nation, there 
was a clear realization that such goals were unrealistic and that Rockefeller no longer 
exercised hegemonic influence over biomedical science as in the past. However, in 1990 
the organization was still a distinguished and major center for biomedical research. Within 
a decade, several of its most creative scientists would be singled out for major 
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recognition—with Nobel Prizes, the Lasker Prize for Basic Biomedical Science, and the 
Louisa Gross Horwitz Prize. Just a few years earlier, Hidesaburo Hanafusa had received the 
Lasker Prize for Basic Biomedical Science. Also, Gerald Edelman had emerged as one of 
the world’s most creative theoreticians in neuroscience, though his work, like any other 
work that is so theoretical, was controversial. While Bruce Merrifield had done the research 
for which he was awarded a Nobel Prize some years earlier, his lab was still very active in 
work involving ever more difficult synthetic challenges and much higher molecular 
numbers. And there were numerous other scientists doing excellent science at the 
University. 
 
 
THE PRESIDENCIES OF TORSTEN WIESEL AND ARNOLD LEVINE 
 
Upon Baltimore’s resignation, the Trustees appointed as President Torsten Wiesel, a 
world renowned neurobiologist who had shared a Nobel Prize in Physiology or Medicine 
with David Hubel in 1981, and who had moved to Rockefeller from the Harvard Medical 
School in 1983. The Trustees could not have found a more suitable person for the task. 
Wiesel, who served until 1998, was an excellent President, one of the very best in the 
history of the organization. 
Wiesel, born and educated in Sweden, had moved to America in 1955. When he 
became President of Rockefeller, he was sixty-seven years old and immediately became 
completely focused on serving the University. Wiesel had many of the traits of an 
outstanding president—a good sense of the direction in which science was moving, a keen 
ability to identify talent and to raise money to support good science, and a capacity to 
create a nurturing environment for both senior and junior scientists. After the intense 
cleavages of the Baltimore Presidency, the Rockefeller faculty were eager to have stability 
and harmony and to rebuild their damaged reputation. Wiesel, an eminent scientist with 
considerable modesty and humility, was highly successful in bringing people together. 
Almost intuitively he was able to integrate the traditions of Rockefeller University with the 
directions in which science was changing as it moved toward the twenty-first century. Early 
in his presidency, he encouraged open faculty participation in discussions of both the 
weaknesses and strengths of the University. He then coordinated the development of an 
Academic Plan, an effort involving unprecedented collaboration between faculty, 
administration, and trustees. His strategy of bringing all parties to the table was typical of a 
rather low-key management style, very different from the bombastic style of Bronk. Very 
quickly, a consensus emerged that the University would build on its current seventy 
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laboratories, and slowly expand to between eighty and a hundred labs as resources became 
available and appropriate talent was identified (Rockefeller University, 1994; interviews 
with Baker, Blöbel, Bowen, Furland, Imhoff, Kandel, Montgomery, Pillsbury, Rockefeller, 
Wiesel, Zinder). 
Since the University was structured around laboratories rather than departments, a 
critical problem was how to keep the centrifugal forces created by so many different labs 
from becoming unmanageable. It was almost as though Wiesel had an innate ability to 
solve the problem. He understood that with so much diversity, it was necessary to have an 
ambidextrous style of management. A major key for coordinating so much diversity was to 
emphasize the tradition and culture of excellence which had been institutionalized at 
Rockefeller. Through the use of a broad array of rituals, the organization throughout the 
1990s highlighted its strong, widely shared culture, a process which helped to promote 
harmony and communication between the different laboratories. Without a strongly shared 
culture, it would have been much more difficult to generate the trust and predictability 
necessary for a well-functioning organization. 
In addition to the emphasis on the common culture, the University also promoted 
the coordination of labs by grouping them around seven research centers, in recognition of 
the natural affinities among the interests of scientists. These centers were financed in part 
by successful University fund-raising in the private sector during the 1990s. The seven 
centers were (1) the Center for Biochemistry and Structural Biology, (2) the Center for 
Sensory Neuroscience, (3) the Center for Human Genetics, (4) the Center for Research on 
Alzheimer’s Disease, (5) the Center for Studies in Physics and Biology, (6) the Center for 
Immunology and Immune Diseases, and (7) the Center for Mind, Brain, and Behavior 
(Rockefeller University, 1994; New Research Programs, 1997; Brennan, 1999). The centers 
were intended to enhance communication and strengthen collaboration across labs, and to 
provide coherence for fund-raising from both federal and private sector sources. Depending 
on their interests, scientists could be affiliated with more than one center. In the process of 
developing the centers, some faculty gained a much better understanding of the 
complementary interests of different labs. The centers have varied in their performance, as 
well as in size and resources, but they have provided a meaningful strategy for promoting 
communication across laboratories. The functioning of the centers has been complemented 
by the fact that in recent years, labs at Rockefeller have become somewhat smaller, 
reducing their tendency to be so internally focused.  
While governance of the University is shared by the labs, the research centers, the 
Academic Council, and the University Senate, the office of the president plays an 
extremely important role in governance by making financial and personnel decisions, and 
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in determining the allocation of laboratory space and laboratory budgets (if non-grant funds 
are being used). During Wiesel’s first four and a half years as President, the University 
raised approximately $135 million in private gifts and pledges, much of which was used to 
support the recruitment of new faculty and to create state-of-the-art laboratories. The 
University increased the number of laboratories and recruited a number of junior and senior 
scientists. During these same years, twenty new laboratories were headed by non-tenured 
scientists.  
When Wiesel left the presidency in 1998, there was a widespread perception both 
within and beyond the University that Rockefeller was once more in a very sound 
condition, both scientifically and financially. The University had restored stability to its 
budgets and operations, and had increased its endowment by over 50 percent in a five-year 
period. Part of this increase resulted from the performance of the American economy, but 
much of the improvement was due to the management team Wiesel and the Trustees had 
put in place (Rockefeller University Annual Reports, 1997, 1998; interviews with Bowen, 
Imhoff, Baker, Furland). 
Very mindful of the turmoil and embarrassments of the early 1990s, by the turn of 
the new century the University was anything but complacent. There was a tone of 
rebuilding, but with modesty as the University attempted to learn from its competitors. In 
retrospect, perhaps the previous turbulence had been healthy for the University, as one of 
its effects had been to create more of a community among its faculty than had existed at 
any time for decades. 
To lead Rockefeller into its second century, in 1998 the Trustees appointed Arnold 
Levine as President, a distinguished cancer researcher and former Chair of the Department 
of Molecular Biology at Princeton University. Levine epitomizes the Rockefeller scientist, 
as he internalizes a great deal of scientific diversity (with broad knowledge of molecular 
biology, cell biology, and genetics) and has a good awareness of the history of various 
fields of science. Rockefeller has come full circle. As was the case with the first director, 
Simon Flexner, Levine thinks strategically. He has a good sense of where science is 
moving, is very conscious of where he wants to direct the University, is keen to promote 
the training of young scientists, and heads an organization which for the moment has 
substantial funding and relatively high morale. 
At the same time, the Rockefeller organization has undergone profound changes 
over the past century. Even in its recent past, there has been exponential growth in its 
infrastructure, with hundreds of research associates, postdocs, technicians, and other 
support staff. However, it is still very small relative to other American universities, with 
around fifty full professors, twenty-seven associate professors, and fifty-three assistant 
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professors (Brennan, 1999: 47). Because of its small faculty, there is far more frequent and 
intense communication among a larger proportion of its scientific staff across diverse fields 
of science than at any other American research university. True, Rockefeller is more 
fragmented than it was forty years ago because it has so many labs, but it is much less 
differentiated internally than every other American university. The fact that there are still 
no departments and that a lab is likely to close down when the head of the lab departs 
means that the organization has an extraordinary flexibility to adapt to the fast pace of 
change in the global environment of science. 
This flexibility and adaptiveness explain why Rockefeller University, despite its 
small size, still towers over most research organizations in America. It has a higher 
proportion of its faculty as either members of the National Academy of Sciences or Howard 
Hughes investigators than any other research organization in America. Moreover, in an 
intensely competitive funding environment, its scientists receive more funding for 
biomedical research per scientist from the National Institutes of Health than scientists in 
any other research organization in America. In 1999 and 2000, Rockefeller University 
demonstrated that its extraordinary excellence as a center for major discoveries is still very 
much alive when members of its faculty received four of the most coveted prizes in 
biomedical science: Robert Roeder received the Louisa Gross Horwitz Prize in basic 
biomedical science, Roderick MacKinnon received the Lasker Prize for Basic Biomedical 
Science, and Günter Blobel in 1999 and Paul Greengard in 2000 received the Nobel Prize 
in Physiology or Medicine. These four prizes in a two-year period represent more 
recognition for major discoveries than most of the leading American research organizations 
received in the whole of the twentieth century (Hollingsworth, Hollingsworth, and Hage, 
2002 forthcoming). In short, at the turn of the millennium there was excellent evidence that 
Rockefeller University is still one of the world’s premier biomedical research organizations 
and is still receiving more recognition for major discoveries in biomedical science than any 
other organization. 
 
 
CONCLUDING OBSERVATIONS 
 
This case study of the Rockefeller suggests that the following factors are associated 
with organizations which have fundamental breakthroughs time and time again across a 
number of decades:  
Organizational flexibility: Knowledge changes rapidly, and if an organization is to 
be continuously at the frontiers of fundamental new knowledge, it must be highly flexible 
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so that it can frequently move into new areas of research. Most research organizations, 
hampered by organizational inertia, have great difficulty being flexible enough to develop 
fundamental new knowledge or to operate continuously at the frontiers of knowledge. Most 
organizations experience a great deal of organizational inertia, tending to reproduce 
research units or traditions when scientists retire or resign, rather than moving into new 
research areas. 
Scientific diversity and integration: Organizations which make major breakthroughs 
time and time again are those with a moderately high degree of scientific diversity. For 
fundamental breakthroughs to occur time and time again in an organization, scientists in 
diverse fields must have intense and frequent interactions with one another. In short, there 
must be a good degree of scientific integration. How this is attained varies from 
organization to organization, but the integration of scientific diversity is facilitated by 
scientists’ socializing with each other. Examples are the sharing of lunch and/or tea, 
scientific retreats, journal clubs held jointly by different research units, or lectures which all 
the scientific staff are expected to attend. For intense and frequent interaction to occur on a 
scale comparable to that at the Rockefeller, an organization’s scientific staff must avoid 
absences of weeks or months at a time.  
Leadership: If an organization is to have major breakthroughs over a long period of 
time, a particular kind of leadership is needed—leaders with a good sense of the direction 
in which science is moving, the ability to identify talent, to skill to facilitate the movement 
of the organization in the desired direction, the ability to generate funding to move into new 
fields of knowledge, and, finally, the capacity to provide a nurturing environment (an 
environment in which there is rigorous criticism, meted out with a high degree of 
sensitivity).  
At the Rockefeller, the president has always been directly involved in the 
recruitment and promotion of all permanent staff. All presidents not only provided 
scientific leadership, but were also involved in the administration of the organization. The 
philosophy of the Rockefeller was (and still is) that the scientific agenda had to be well 
integrated with administrative services, and the best way for this to occur was for the same 
person to direct the scientific and administrative activities.  
Recruitment: The Rockefeller had extremely high standards for making permanent 
appointments. For many years, for every young scientist who was promoted internally to a 
permanent appointment, there were between twenty and twenty-five scientific staff who 
were not retained. Indeed, the Rockefeller historically has treated every permanent staff 
position as its most precious asset. Not only has the president been intimately involved in 
every permanent appointment, but the president historically has had the right to veto an 
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appointment, and over the years has exercised this veto power frequently. In addition, the 
Rockefeller has always depended on external advisors in the making of permanent 
appointments. During the first fifty years, there was a board of scientific directors made up 
of some of the most distinguished scientists in America, and not a single appointment was 
made without their extensive participation. During the last half century, the board of 
trustees has included a group of distinguished scientists and they, too, have been intimately 
involved in exercising oversight over permanent scientific appointments. They have 
frequently exercised veto over appointments which they have considered of insufficiently 
high quality.  
Historically, most senior scientists at the Rockefeller have been promoted through 
the ranks. Indeed most, though not all, of the Nobel prizes awarded to the Rockefeller staff 
went to scientists who arrived at the Rockefeller as very young scientists and who rose to 
be world-class scientists at the institution. Very few of its most distinguished scientists 
were recruited from the outside as senior scientists. 
Organizational autonomy: The Rockefeller University has been embedded in a weak 
institutional environment during most of its history. As a result, it has had the capacity to 
appoint scientists to senior positions without being constrained by externally imposed 
norms of credentialing (e.g., habilitation, formal training in the fields of appointment), and 
the organization has been relatively independent of control by state bureaucracies and their 
rules. Because of its autonomy, it has had a high degree of flexibility to carry out almost 
any line of activity which its leaders have wanted to conduct. 
Finally, the excellence of the Rockefeller has been due to the fact that it has had a 
very rich learning environment. Its staff have long been engaged in educating one another 
across fields. A great research organization is one in which most of the participants have a 
high degree of curiosity about, and familiarity with, what all the permanent staff in the 
organization are doing. At the same time, the Rockefeller has been a rich training 
environment for young people recruited primarily as young postdoctoral scholars, who have 
been expected to move on after three or four years at the most. Part of the Rockefeller’s 
great learning excitement has resulted from the fact that its senior and junior staff have 
been recruited from many parts of the world, and this cultural diversity, added to its 
scientific diversity, has enhanced very high levels of creativity within the organization.  
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APPENDIX ONE 
 
SCIENTISTS WHOSE MAJOR DISCOVERIES, ALL OR PART, WERE MADE AT 
ROCKEFELLER INSTITUTE/UNIVERSITY  
AND THE FORMS OF RECOGNITION FOR THEM 
 
Name of Scientist Forms of Recognition 
Oswald Avery 1 Nominated 10 times in three different years for Nobel Prize in 
Physiology or Medicine 1931.2 For the discovery that the 
immunological specificity of type II pneumococcus is due to a 
polysaccharide. 
Copley Medal 1945. For recognizing the transforming principle of 
DNA. 
Günter Blobel Horwitz Prize 1987; Lasker Prize 1993; Nobel Prize in Physiology 
or Medicine 1999. For his discovery that proteins have intrinsic 
signals that govern their transport and localization in the cell. 
Alexis Carrell Nobel Prize in Physiology or Medicine 1912. For his work in 
suturing blood vessels and in the transplantation of organs. 
Albert Claude Horwitz Prize 1970; Nobel Prize in Physiology or Medicine 1974. 
For applying the techniques of centrifugation and electron 
microscopy to the isolation and identification of subcellular 
structures. 
Lyman Craig Lasker Prize 1963. For his countercurrent distribution technique as 
a method for the separation of biologically significant compounds, 
and for the isolation and structure studies of important antibiotics. 
Christian de Duve Nobel Prize in Physiology or Medicine 1974. For combining 
subcellular fractionation with biochemical analysis in order to 
discover the cell organelles of lysosome and peroxisome and for 
identifying their functions. 
Gerald Edelman Nobel Prize in Physiology or Medicine 1972. For determining for 
the first time the complete chemical structure of immunoglobulins 
(antibodies), the key molecules of immunity. 
Simon Flexner Nominated 10 times in three different years for Nobel Prize in 
Physiology or Medicine 1911.2 For developing serum treatment of 
cerebrospinal meningitis. 
Paul Greengard Nobel Prize in Physiology or Medicine 2000. For his discoveries 
concerning signal transduction in the nervous system. 
Hidesaburo 
Hanafusa 
Lasker Prize 1982. For demonstrating how RNA tumor viruses 
cause cancer, and elucidating their role in combining, rescuing and 
maintaining oncogenes in the viral genome. 
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H.K. Hartline Nobel Prize in Physiology or Medicine 1967. For work on the 
physiology and chemistry of vision. 
Bertil Hille 3 Horwitz Prize 1976; Lasker Prize 1999. For elucidating the 
functional and structural architecture of ion channel proteins, which 
govern the electrical potential of membranes throughout nature, 
thereby generating nerve impulses and controlling muscle 
contraction, cardiac rhythm, and hormone secretion. 
Henry Kunkel Lasker Prize 1975; Horwitz Prize 1977. For his discoveries in 
immuno-pathology. 
Karl Landsteiner Nobel Prize in Physiology or Medicine 1930. For his classification 
of blood groups and for his further discoveries over the years of 
subgroups within the original groups which he identified.  
Jacques Loeb Nominated 10 times in three different years for Nobel Prize in 
Physiology or Medicine 1911.2 For his research on the colloidal 
behavior of proteins. 
Roderick 
MacKinnon 
Lasker Prize 1999. For elucidating the functional and structural 
architecture of ion channel proteins, which govern the electrical 
potential of membranes throughout nature, thereby generating nerve 
impulses and controlling muscle contraction, cardiac rhythm, and 
hormone secretion. 
Bruce Merrifield Lasker Prize 1969; Nobel Prize in Chemistry 1984. For his 
development of a simple and ingenious method for synthesizing 
peptides and proteins. 
Stanford Moore Nobel Prize in Chemistry 1972. For research on enzymes, body 
proteins central to life; particularly for working out for the first time 
the chemical structure of pancreatic ribonuclease, an enzyme that 
breaks down ribonucleic acid (RNA). 
Hideyo Noguchi Nominated 10 times in three different years for Nobel Prize in 
Physiology or Medicine 1921.2 For his research in demonstrating 
the relationship between Oroya Fever and verruca peruviana and 
cultivation of the causative agent. 
John Northrop Nobel Prize in Chemistry 1946. For the preparation of enzyme and 
virus proteins in pure form. 
George Palade Lasker Prize 1966; Horwitz Prize 1970; Nobel Prize in Physiology 
of Medicine 1974. For contributing important techniques of 
centrifugation and electron microscopy and using them to define 
how cells synthesize proteins and how they package proteins for 
secretion. 
Keith Porter Horwitz Prize 1970. For his fundamental contributions to the 
electron microscopy of biological materials. 
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Robert Roeder Horwitz Prize 1999. For his research on the processes of gene 
activation. 
Peyton Rous Nobel Prize in Physiology or Medicine 1966. For establishing a 
virus as the cause of chicken sarcoma. 
Theobald Smith  Nominated 10 times in three different years for Nobel Prize in 
Physiology or Medicine 1921;2 Copley Medal 1933. For his 
research on host-parasite interrelationships. 
Wendell Stanley Nobel Prize in Chemistry 1946. For the preparation of enzyme and 
virus proteins in pure form. 
William Stein Nobel Prize in Chemistry 1972. For research on enzymes, body 
proteins central to life; particularly for working out for the first time 
the chemical structure of pancreatic ribonuclease, an enzyme that 
breaks down ribonucleic acid (RNA). 
 
 
 
1 Oswald Avery received recognition for two major discoveries. One was his work on 
polysaccharides in the 1920s and the other was his work on DNA in the 1940s 
(Dubos, 1976; McCarty 1985; Amsterdamska, 1993; Bearn, 1996; Dale, 1946). 
 
2 Scientists who are included in this study as a result of having 10 nominations in 
three different years are identified as “10 in 3” and the date listed for them is the 
first odd-numbered year in the decade in which they received the largest number of 
nominations. Thus, a scientist receiving two nominations in 1911, three in 1913, and 
five in 1921 would be listed with the year 1921. 
 
3 The body of work for which Hille was recognized was begun while he was a student 
at Rockefeller University. 
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APPENDIX TWO 
SOURCES 
 
INTERVIEWS* 
 
Henry Abarbanel, Professor of Physics and Director of Institute for Nonlinear Science, 
University of California San Diego. Interviews at UCSD Faculty Club, 5 February, 
24 February 1998, 13 July 2001. 
Pnina Abir-Am, Scholar in Residence at Rockefeller Archive Center. Interview at 
Rockefeller Archive Center, 10 May 2001. 
Richard Adamson, former Chief of Cancer Etiology, National Cancer Institute of Health. 
Interview in his office in Washington, D.C., 2 March 1995. 
Michael Aiken, Provost, University of Pennsylvania. Interviews in his office and in his 
home, 18, 19 February 1993. 
Jens Alber, Professor of Administrative Sciences, Konstanz University (Germany). 
Interviews 11 October 1994, 23 November 1994. 
Bruce Alberts, President, National Academy of Sciences. Former Professor of 
Biochemistry and Biophysics, University of California, San Francisco; former 
Professor of Biochemistry, Princeton University. Interview in his office in 
Washington, D.C., 20 November 1995. 
Robert Alberty, Dean Emeritus of Science and Professor Emeritus of Chemistry, MIT. 
Interview in his office, 2 May 1995. 
Vince Allfrey, Emeritus Professor Rockefeller University. Interview in his office, 22 
February 2000. 
Jutta Allmendinger, Professor of Sociology, University of Munich. Interview in her office, 
16 June 1998. 
Fred Appelbaum, Director, Division of Clinical Research, Fred Hutchinson Cancer 
Research Center (Seattle). Interview in his office, 31 July 1995. 
Reginald M. Archibald, Professor Emeritus, Rockefeller University. Interview at 
Rockefeller University, 2 February 2001. 
Ruth Arnon, Professor, Weizmann Institute, Israel. Interview in San Diego, CA, 17 
February 1998. 
Michael Ashburner, Professor of Genetics, University of Cambridge. Interview in his 
office, 9 June 1999. 
Alan Attie, Professor of Biochemistry, University of Wisconsin (Madison). Interview at 
author’s home, 15 November 1996. 
Stratis Avrameas, former Director, Unité d’Immunocytochimie, Institut Pasteur, Paris, 
France. Interview in French in his office 12 May 2000. 
W. Bachtold, President of Research Council, Swiss Federal Institute of Technology (ETH), 
Switzerland. Interview in his office, 12 December 1994. 
William Baker, Chairman of the Board of Trustees Emeritus, Rockefeller University, and 
former head of Bell Labs. Interview at Rockefeller University, 30 January 2001; 
telephone interview 2 February 2001. 
Evan Balaban, Fellow at Neurosciences Institute, San Diego, CA. Former student, 
Rockefeller University. Interviews at Neurosciences Institute, 6 February 1996, 7 
January 1998, 12 April 2000. 
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David Baltimore, Professor of Biology, Massachusetts Institute of Technology, and former 
President of Rockefeller University. Interview in his MIT office, 28 April 1995. 
Michel Barne, former Director of Unité de virologie et vaccins viraux at Institut Pasteur. 
Interview in English in his apartment, 16 March 2000. 
Derek H.E. Barton (Sir), Professor of Chemistry, Texas A and M University and Professor 
Emeritus, Imperial College, London. Interview at the Beckmann Center, Scripps 
Research Institute, La Jolla, CA, 6 February 1998. 
Steve Bass, Biological Scientist, Genentech Inc. Interview at Cold Spring Harbor 
Laboratory, New York, 26 August 1995. 
Bob Bauer, Manager, Advanced Systems Development Laboratory, Xerox Palo Alto 
Research Center. Interview at Scripps Institute of Oceanography, 9 July 2001. 
Alexander Bearn, Executive Director American Philosophical Society; Life Trustee and 
former Professor, Rockefeller University. Interviews in his office, 15 February and 
23 August 2000. 
William Beers, Vice President for Facilities and Research Support, Rockefeller University. 
Interview in his office, 18 May 2001. 
Artur Benz, Professor of Administrative Sciences, Konstanz University (Germany), 30 
November 1994. 
Seymour Benzer, Professor of Biology, California Institute of Technology. Interview in his 
office, 30 March 1994; second interview at Cold Spring Harbor Laboratory, New 
York, 26 August 1995; third interview at Neurosciences Institute, San Diego, CA, 
17 March 1996; fourth interview in his office, 22 December 1999. 
Jean Bernard, former Professor of Medicine, Hôpital Saint-Louis, Paris, France. Interview 
in French in his apartment 17 April 1998. 
Michael Berridge, Professor of Zoology, University of Cambridge. Interview at Trinity 
College, 9 June 1999. 
Howard Birnbaum, Professor of Material Science and Engineering, University of Illinois. 
Interview at Scripps Institute of Oceanography, 9 July 2001. 
J. Michael Bishop, Professor of Microbiology, Director of Hooper Research Laboratory, 
University of California, San Francisco. Interview in his office, 10 August 1994. 
Günter Blobel, Professor at Rockefeller University and HHMI investigator. Interview in his 
office, 12 April 1995. Subsequent interviews in his office, 16 March 2001, 18 
March 2001. 
Konrad Bloch, Professor Emeritus of Biochemistry, Harvard University. Interview in his 
office, 25 April 1995. 
Helmut Blocker, Head of Department, Genome Research, Protein Design, Gesellschaft für 
Biotechnologische Forschung mbH in Braunschweig. Interview in Klosters, 
Switzerland, 17 January 1995. 
Bernard S. Blumberg, Professor, Fox Chase Cancer Center (Philadelphia). Interview at 
Rockefeller Foundation Study Center, Bellagio, Italy, 21 May 1984. 
Michel Boiron, former Professor of Medicine and former Director, Unité de virologie des 
leucémies, Hôpital Saint-Louis, Paris, France. Interviews in his office in French 17 
June 1997 and 12 April 1998. 
Derek Bok, President Emeritus, Harvard University. Interview in his office, 24 April 1995. 
Sir Christopher Booth, Royal College of Physicians. Interview in his office, London, 3 May 
1997. 
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Guy Bordenave, Director, Unité d’Immunophysiologie moléculaire, Institut Pasteur, Paris, 
France. Interview in French in a laboratory 10 May 2000. 
Michel Bornens, Director Laboratory de Cells, Unité mixe de recherche, compartimentation 
et dynamique cellulaire at Institut Curie, Paris. Interview in English in his office on 
27 May 2000. 
David Botstein, Professor, Department of Genetics, Stanford University School of 
Medicine. former Professor of Biology, MIT. Interview at Cold Spring Harbor 
Laboratory, 25 August 1995. 
Fred Bowen, former Executive Vice President, Rockefeller University. Interview at 
Rockefeller University, 14 March 2001. 
Eugene Braumwald, Professor of Medicine, Chief of Medicine, Brigham and Women’s 
Hospital. Interview in his office, 27 April 1995. 
Jan Breslow, Professor, Rockefeller University. Interview in his laboratory, 14 April 2001. 
Second interview, 18 April 2001. 
Gerth Brieger, William H. Welch Professor of History of Medicine, Science, and 
Technology, Johns Hopkins University, Baltimore. Interview in his office, 21 July 
1997. 
Henri Buc, Director, Unité de physicochimie des macromolécules biologiques, Institut 
Pasteur, Paris, France. Interview in French in his office, 6 March 2000. 
Martin J. Bukovac, University Distinguished Professor, Michigan State University, East 
Lansing, MI. Interview in Bonn, Germany, 9 July 1996. 
Stephen K. Burley, Professor and Deputy to the President for Academic Affairs and HHMI 
Investigator, Rockefeller University. Interview in his office, 10 April 2001. 
Beth Burnside, Vice Chancellor for Research, University of California, Berkeley. Interview 
at Scripps Institute of Oceanography, 9 July 2001. 
Robert H. Burris, Professor Emeritus of Biochemistry, University of Wisconsin (Madison). 
Interview in his office, 16 October 1995. 
William J. Butterfield (Baron Butterfield), former Vice-Chancellor, University of 
Cambridge. Interview in his home, 12 July 2000. 
Martin Cadwallader, Associate Dean of Graduate School, University of Wisconsin 
(Madison). Interview in his office, 7 and 8 March 1994. 
Anthony Cerami, Director, Kenneth S. Warren Laboratories and former Professor and Dean 
of Graduate Studies, Rockefeller University. Interviews at Rockefeller Archive 
Center, 12 March 2001, 10 May 2001. 
Henry Chadwick (Sir), former Master, Peterhouse College, University of Cambridge. 
Former Regius Professor, University of Oxford; former Regius Professor, 
University of Cambridge. Many interviews at Rockefeller Foundation Study Center, 
Bellagio, Italy, June 1994. Interview at his home in Oxford, 13 April 1997. 
Margaret Chadwick (Lady). Numerous interviews at Rockefeller Foundation Study Center, 
Bellagio, Italy, June 1994. 
Marsha Chandler, Senior Vice Chancellor for Academic Affairs, University of California, 
San Diego. Interview in her office, 9 March 1998. Other interviews in La Jolla, 
California, 7 December 2000, 12 July 2001. 
Jean-Pierre Changeux, Director, Unité de neurobiologie moléculaire, Institut Pasteur, Paris, 
France. Interview in French in his office, 25 April 2000. 
Erwin Chargaff, Professor Emeritus of Biochemistry, Columbia University. Interview at his 
home in New York City, 19 November 1993. 
 71  
J. ROGERS HOLLINGSWORTH 
John Child, Professor of Judge School of Management, University of Cambridge. Interview 
in Stresa, Italy, 11 September 1997. 
Purnell Choppin, President Emeritus, HHMI, and former Professor, Rockefeller University. 
Interview at Rockefeller University, 14 November 2000. 
Philippa Claude, Senior Scientist, Department of Zoology, University of Wisconsin, 
Madison, and daughter of Albert Claude. Interview in her office, 13 March 2000. 
George Cohen, former Director, Unité de biochimie cellulaire, Institut Pasteur, Paris, 
France, and former Director, Laboratoire d’Enzymologie, CNRS, Gif-sur-Yvette, 
France. Both interviews in his office, the first in French on 9 March 2000 and the 
second in English on 9 June 2000. 
Joel Cohen, Professor, Rockefeller University. Interview in his office, 8 February 2001. 
Mildred Cohen, Professor Emeritus of Bio-physics, University of Pennsylvania. Interview 
in her office, 31 August 1993. 
Melvin Cohn, Professor Emeritus, Salk Institute. Interview in his office, 5 December 2000. 
Randall Collins, Professor, Department of Sociology, University of California, Riverside. 
Interview at Royal Swedish Academy of Science, Stockholm, Sweden, 26–27 
September 1996. 
Karen Cook, James B. Duke Professor, Duke University. Numerous interviews, Rockefeller 
Foundation Study Center, Bellagio, Italy, May and June 1996. 
Patrice Courvalin, Director of Unité des antibactériens at Institut Pasteur, Paris, France. 
Interview in his office in English, 25 February 1998. 
Andrew Crawford, Professor of Physiology, University of Cambridge. Interview at 
University of Wisconsin (Madison), 26 June 2000. 
Angela Creager, Professor of History, Princeton University. Interview at Bancroft Library, 
University of California, Berkeley, 12 August 1994. 
Francis Crick, President Emeritus and Distinguished Professor, Salk Institute; former 
scientist at Cambridge University and at the Laboratory of Molecular Biology. 
Interview in his office in San Diego, 6 March 1996 and 11 March 1998. 
Odile Croissant, maître de recherche, CNRS, Institut Pasteur, Paris, France. Interview in 
conference room in French, 18 April 2000. 
E. David Cronon, Dean Emeritus of College of Letters and Sciences and Professor 
Emeritus of History. Interview at the University Club, University of Wisconsin, 17 
March 1994. 
Kathryn Crossin, Section head of Neurobiology Lab, Scripps Research Institute. Former 
postdoc at Rockefeller University. Interview at Neurosciences Institute, San Diego, 
19 January 1996. 
James Crow, Professor Emeritus of Genetics, University of Wisconsin (Madison). 
Interview in his office, 10 November, 1993. 
Bruce Cunningham, Professor Scripps Research Institute, San Diego, CA. Former 
Professor, Rockefeller University. Interviews at Neurosciences Institute, 7 February 
1996 and 11 March 1998. 
James E. Darnell, Jr., Professor, Rockefeller University. Interview in his office, 10 April 
1995. Other interviews in his office, 8 March 2001, 18 April 2001, 29 May 2001. 
Robert Darnell, Professor, Rockefeller University. Interview in his office, 25 January 2001. 
Eric Davidson, Professor of Biology, California Institute of Technology, and former 
Associate Professor at Rockefeller University. Interview in his office, 5 May 2000. 
 72 
RESEARCH ORGANIZATIONS AND MAJOR DISCOVERIES 
Lance Davis, Professor of Economics, California Institute of Technology. Interview in his 
office, 28 March 1994. 
Scott Davis, Associate Director, Division of Public Health, Fred Hutchinson Cancer Center 
(Seattle). Interview in his office, 1 August 1995. 
Robert Day, Director, Fred Hutchinson Cancer Research Center. Telephone interview, 20 
July 1995. 
Soraya de Chadarevian, Department of Philosophy and History of Science, Cambridge 
University. Interview, 4 November 1998. 
Titia De Lange, Professor at Rockefeller University. Interviews in her office, 6 April 2001, 
10 April 2001. 
Manny Delbruck, (wife of Max Delbruck), Pasadena, CA. Interview at Cold Spring Harbor 
Laboratory, New York. Interview, 26 August 1995. 
Hector F. DeLuca, Harry Steenbock Professor of Biochemistry, University of Wisconsin 
(Madison). Interview in his office, 17 March 1994. 
Robert De Mars, Tracy Sonneborn Professor of Genetics, University of Wisconsin 
(Madison). Interview 14 December 1997 by telephone. 
Pierre Devillers, former Member of the Directorate of INSERM, Institut Curie, Paris, 
France. Interview in his office in French, 15 May 2000. 
Carl Djerassi, Professor of Chemistry, Stanford University. Interview in Madison, WI, 18 
May 1995. Second interview October 7, 1997 in Department of Chemistry, 
University of Wisconsin (Madison). 
Paul Doty, Professor Emeritus of Biochemistry, Harvard University. Interview in his office, 
3 May 1995. 
Renato Dulbecco, Emeritus President and Distinguished Professor, Salk Institute; former 
Professor, California Institute of Technology. Interview in his office in San Diego, 
23 February 1996. Second interview in his office, 22 May 2000. 
Isabelle Dusanter, Research Director at INSERM, Paris, France. Interview at lunch, in 
English, 27 March 2000. 
Walter Eckhart, Professor Salk Institute. Interview in his laboratory, 23 May 2000. 
Gerald Edelmann, Research Director, Neuroscience Institute, San Diego, CA and former 
Professor and Dean, Rockefeller University. Interviews in Klosters, Switzerland, 17 
January 1995, and at Neurosciences Institute, 13 January, 16 January, 19 January, 
30 January, 14 February, 20 February, 22 February, 5 March, 16 March, 17 March 
1996; 12 February 1998; 4 April, 11 April, 18 November 2000. Interview by phone 
3 April 2001. 
Mark Edinger, Professor of Chemistry, University of Wisconsin. Interview at O’Hare 
Airport, Chicago, 19 August 1995. 
John Edsall, Professor Emeritus of Biochemistry, Harvard University. Interview in his 
office, 4 May 1995. 
Manfred Eigen, Professor, Max-Planck Institut für biophysikalische Chemie, Göttingen, 
Germany. Interview in Klosters, Switzerland, 16 January 1995. 
Gertrude Elion, Scientist Emeritus, The Wellcome Research Laboratories, Research 
Triangle Park, NC. Interview in her office, 17 March 1995. 
Franklin Epstein, Professor of Medicine, Harvard Medical School, and former Chief of 
Medicine, Beth Israel Hospital. Also former Professor of Medicine, Yale 
University. Interview in his office at Beth Israel Hospital, 26 April 1995. 
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Tom Everhart, President, California Institute of Technology. Interview at the Athenaeum at 
the California Institute of Technology, 21 December 1994. 
Marilyn G. Farquhar, Professor of Cellular and Molecular Medicine, University of 
California San Diego, and former Professor, Rockefeller University. Interview in 
her office, 25 May 2000. 
Eugenio Ferrari, Scientist, Genentech Inc. Interview at Cold Spring Harbor Laboratory, 
New York, 26 August 1995. 
Gerald R. Fink, Director, Whitehead Institute for Biomedical Research and Professor of 
Biology, MIT. Interview in his office, 4 May 1995. 
Roberto Franzosi, Fellow of Trinity College, University of Oxford, UK. Interview at his 
home, 12 April 1997. 
Hans-Joachim Freund, Heinrich Heine University, Düsseldorf, Germany. Interview at 
University of California, San Diego Faculty Club, 20 February 1998. 
Jock Friedly, Freelance Journalist. Telephone interview, 4 September 1994; second 
interview in Washington, D.C., 22 August 1995. 
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his office, 16 March 2001. Second interview 18 April 2001. 
Richard Furlaud, former Chair, Board of Trustees, Rockefeller University (1990–1998), 
Member of Board of Trustees (1976–1998), President of Rockefeller Council 
(2001). Interview at Rockefeller University, 17 May 2001. 
Edward Furtek, Associate Vice Chancellor for Science and Technology Policy and 
Projects, University of California, San Diego. Interview at his office, 9 July 2001. 
Daniel Carleton Gajdusek, Chief of the Laboratory for Slow Latent and Temperate Virus 
Infections and Chief of the Laboratory for Control Nervous System Studies at the 
National Institute for Neurological Disorders and Stroke. Interview at 
Neurosciences Institute, San Diego, CA, 11 March 1996. 
Robert Galambos, Professor Emeritus of Neuroscience, University of California, San 
Diego. Interview at UCSD Faculty Club, 13 March 1998. 
Einar Gall, Director, Neurosciences Institute, San Diego, CA. Interviews at the 
Neurosciences Institute, 15 March, 1996, 7 January 1998, 6 February and 17 
February 1998. 
Joe Gally, Senior Fellow, Neurosciences Institute, San Diego, CA, and former graduate 
student at Rockefeller University. Multiple interviews at the Neurosciences 
Institute, during visits at the Institute in 1996, 1998, and 2000. 
Robert Gallo, Chief of the Laboratory of Tumor Cell Biology, National Institutes of Health, 
Bethesda, MD. Interview at University of Wisconsin Union, 13 March 1994. 
Interview in Bethesda, MD, 29 June 1994. Interviews in his office, 31 August 1994, 
4 September 1994, 4 March 1995, 17 November 1995. 
Walter Gilbert, Carl M. Loeb University Professor at Harvard University. Interview in 
Chicago, 14 October 1993. Interview in his office at Harvard University, 26 April 
1995. 
Alex Glazer, Professor and Chair, Department of Molecular and Cell Biology, University 
of California, Berkeley. Interview in his office, 4 January 1995. 
Ian M. Glynn, Emeritus Professor and Head, Department of Physiology, University of 
Cambridge. Interview in his room at Trinity College, 12 July 2000. 
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Technology. Interview in his office, 29 March 1994. 
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Max-Planck-Institut für Gesellschaftsforschung in Cologne, Germany, 7 July 1996. 
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June 1999. 
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Joel Grossman, Professor of Political Science, Johns Hopkins University, Baltimore. 
Interviews 18, 19 and 20 July 1997; 28 and 29 December 1999. 
Roger Guillemin, Professor, Salk Institute. Interview in his office, 8 May 2000. 
Robert Gunn, Professor and Chairman of Department of Physiology, Emory University, 
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University of Wisconsin, 18 December 1997. 
Bernadine Healy, former Director of National Institutes of Health. Telephone interview, 4 
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School of Medicine, University of California, San Diego. Telephone interview, 18 
February 1995 and interview at his home in San Diego, 14 March 1996. 
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David Horvath, Associate Dean, Letters and Sciences, University of Wisconsin (Madison). 
Interview in his office, 19 March 1998. 
Rollin C. Hotchkiss, Professor Emeritus, Rockefeller University. Interview in Chicago, 14 
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Interview in her office, 10 August 1994. 
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in his office, 14 October 1995. 
Maren E. Imhoff, Vice President for Development, Rockefeller University. Multiple 
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Kristina Johnson, Dean, School of Engineering and Professor of Bio-Engineering, Duke 
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Rockefeller University. Interview at Columbia University, 19 April 2001. 
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Professor of Medicine, Biochemistry and Biophysics, University of Pennsylvania. 
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Patrick Kenis, Professor of Administrative Science, Konstanz University (Germany), 24 
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Julius Krevans, former Dean, School of Medicine, University of California, San Francisco. 
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Gilbert Kukielka, Research Fellow in Cardiology, Johns Hopkins University, Baltimore. 
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at Scripps Institute of Oceanography, 8 July 2001. 
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(Madison). Interview in his office, 8 November 1993. 
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Interview in his office, 8 June 1999. 
Philippe Lazar, former Director of INSERM, Paris, France, Interview in his office at 
ORSTOM, in French, 30 March 2000. 
Joshua Lederberg, President Emeritus, Rockefeller University. Former Chair, Medical 
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interviews in his office, 25 January 2001, 4 April 2001. 
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Richard Lerner, President of Scripps Research Institute, San Diego. Interviews in his office, 
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Rita Levi-Montalcini, Professor Emeritus of Biology, Washington University (St. Louis). 
Interview at her home in Rome, Italy, 15 June 1995. 
Arnold Levine, President, Rockefeller University. Interview in his office, 14 May 2001. 
Myron Levine, Department of Human Genetics, University of Michigan Medical School. 
Interview at Cold Spring Harbor Laboratory, New York, 24 August 1995. 
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Roderick MacKinnon, Professor, Rockefeller University and HHMI Investigator. Interview 
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Enid A.D. MacRobbie, Professor of Plant Sciences, University of Cambridge. Interview in 
her office, 11 June 1999. 
Boris Magasanik, Jacques Monod Professor Emeritus of Biology at MIT, former Chairman, 
Department of Biology, MIT. Interview at Cold Spring Harbor Laboratory, New 
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Hubert Markl, President, Max-Planck-Gesellschaft zur Förderung der Wissenschaften, 
Munich, Germany. Interview in Bonn, Germany, 9 July 1996; second interview in 
his office in Munich, 15 June 1998. 
Laurence J. Marton, former Professor at University of California, San Francisco School of 
Medicine, and former Dean, School of Medicine, University of Wisconsin 
(Madison). Interviews in his Madison office, 2 August 1994, 13 October 1995. 
Charles Massey, former Senior Vice President, National Foundation. Interview by 
telephone, 29 October 2001. 
Karl Ulrich Mayer, Director, Max-Planck-Institut für Bildungsforschung, Berlin. Interview 
in his office, 5 July 1996. 
Maclyn McCarty, Professor Emeritus and Vice President Emeritus, Rockefeller University. 
Interview in his office, 6 February 2001. 
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Sheila McMichael (Lady) (Dr. Sheila Howarth), former Executive Officer of Medical 
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(London), 9 May 1997. 
Peggy Means, Chief Operating Officer, Fred Hutchinson Cancer Research Center (Seattle). 
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Fritz Melchers, Director, Basel Institute of Immunology (Switzerland). Interviews in his 
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Bruce Merrifield, John D. Rockefeller, Jr. Emeritus Professor, Rockefeller University. 
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Robert Merton, University Professor, Columbia University. Interview at Russell Sage 
Foundation, New York City, 19 April 1995. 
Robert Metzenberg, Bascom Professor Emeritus of Biomedical Chemistry, University of 
Wisconsin (Madison). Interview in his office, 28 February 1995. 
Pierre Meystre, Professor, Max-Planck-Institut für Quantenoptik, Garching, Germany; 
Optical Sciences Center, University of Arizona. Interview in Bonn, Germany, 8 July 
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George Miklos, Senior Fellow, Neurosciences Institute, San Diego, California. Interview at 
Neurosciences Institute, 16 January 1996. 
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February 2000. Interview by telephone, 15 March 2000. 
Peter Model, Professor of Rockefeller University. Interviews at Rockefeller University, 26 
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Neurosciences Institute, 7 January 1998. 
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Jack Morrell, Emeritus Reader, Bradford University. Interview at his home, 12 June 1999. 
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of Sciences, Stockholm, Sweden, 27 September 1996. 
Vernon Mountcastle, Professor of Medicine, Johns Hopkins University. Interview 7 March 
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Tom Muir, Head of Laboratory of Synthetic Protein Chemistry, Rockefeller University. 
Interview in his office, 28 February 2001. 
Shigetada Nakanishi, Professor, University of Kyoto Medical School, Kyoto, Japan. 
Interview in his office, 30 October 1997. 
Dan Nathans, Professor, Department of Molecular Biology and Genetics, Johns Hopkins 
University, Baltimore. Interview in his office, 21 July 1997. 
William Neaves, Chief Executive Officer, Stowers Institute for Medical Research, Kansas 
City, MO. Interview in his office, 22 March 2001. 
Paul Neiman, Director, Division of Basic Sciences and Program in Molecular Medicine, 
Fred Hutchinson Cancer Research Center (Seattle). Interview in his office, 31 July 
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Richard Nelson, Professor of Economics and Political Science, Columbia University. 
Interview at Columbia University, 23 February 2001. 
Hans Neurath, Professor of Biochemistry, University of Washington School of Medicine. 
Interview in his office, 3 August 1995. 
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(Stockholm). Interviews at Scripps Research Institute, San Diego, 26 February 
1996; Royal Swedish Academy of Sciences, Stockholm, Sweden, 26–27 September 
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Leslie Orgel, Professor, Salk Institute of Biological Studies. Interview in his office, 18 May 
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Ray Owen, Professor of Biology, California Institute of Technology. Interview in his 
office, 22 December 1994. 
George Palade, Dean of Medical School, University of California, San Diego; former 
Professor at Yale University and Rockefeller University. Interviews in his office in 
San Diego, 7 March 1996, 13 March 1998. 
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Biology, 11 June 1999. 
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Joseph Perpich, Vice President for Grants and Special Projects, HHMI, Chevy Chase, MD. 
Interview in his office, 6 March 1995. 
Robert Petersdorf, former Chair, Department of Medicine, University of Washington 
School of Medicine; former Dean of School of Medicine, University of California, 
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Harry L. Peterson, Vice Chancellor, University of Minnesota. Telephone interview, 17 
March 1994. 
Marnie Pillsbury, Trustee of Rockefeller University. Interview in her office at Rockefeller 
Center, 30 May 2001. 
Van Potter, Hilldale Professor Emeritus of Oncology, University of Wisconsin (Madison). 
Interviews at McArdle Cancer Laboratory, University of Wisconsin (Madison), 26 
November 1993, 13 April 1995. 
Hans-Wolfgang Presber, Vice President for Medicine, Humboldt University, Berlin, 
Germany. Interview in his office, 25 June 1998. 
Peter Preuss, President of the Preuss Foundation and Regent of the University of California. 
Interview at Scripps Institute of Oceanography, 8 July 2001. 
Mark Ptashne, Professor, Memorial Sloan-Kettering Cancer Center, and former Professor 
and Chair, Department of Biochemistry and Molecular Biology, Harvard 
University. Interview in his New York City apartment, 24 May 2001. 
Beverly Purnell, Max-Planck-Institut für biophysikalische Chemie in Göttingen, Germany, 
and Department of Biochemistry and Molecular Biology, Pennsylvania State 
University. Interview in Bonn, Germany, 9 July 1996. 
Jeffrey W. Purnell, Max-Planck-Institut für biophysikalische Chemie in Göttingen, 
Germany, and Department of Chemistry, Pennsylvania State University. Interview 
in Bonn, Germany, 9 July 1996. 
Ronald Raines, Professor of Biochemistry, University of Wisconsin (Madison). Interview 
at author’s home, 15 November 1996. 
Hans-Jörg Rheinberger, Director of the Max-Planck-Institut für Wissenschaftsgeschichte, 
Berlin. Interview in his office, 29 June 1998. 
Alex Rich, William Thompson Sedgewick Professor of Biology, MIT. Interview in his 
office, 28 April 1995. 
George Rieke, Associate Professor, Rockefeller University. Interview 25 April 2001. 
Hans Ris, Professor of Zoology, University of Wisconsin (Madison), and former postdoc at 
Rockefeller University. Interview in his office, 15 March 2000. 
Nancy Rockafeller, Professor of History of Medicine, University of California, San 
Francisco. Interview in her office, 10 August 1994. 
David Rockefeller. Interview in his office, New York, 24 July 1997. 
Robert Roeder, Professor at Rockefeller University. Interviews at Rockefeller University 24 
April 2001, 8 May 2001. 
John Ross, former Chair, Departments of Chemistry, Massachusetts Institute of Technology 
and Stanford University. Interview at Neurosciences Institute, 18 February 1998. 
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Sheldon Rothblatt, Director of the Center for Studies of Higher Education, University of 
California, Berkeley. Interview in his office, 5 January 1995. 
Henry Rozovsky, former Dean, College of Arts and Sciences, Harvard University. 
Telephone interview, 2 May 1995. 
Harry Rubin, Professor of Molecular and Cell Biology, University of California, Berkeley. 
Interview in his office, 4 January 1995. 
Martin Rudwick, Geologist and Professor of History, University of California, San Diego. 
Interview at University of California San Diego Faculty Club, 10 February 1998. 
Marjorie Russell, Associate Professor, Rockefeller University. Interview at Rockefeller 
University, 8 May 2001. 
William Rutter, Professor Emeritus of Biochemistry and Biophysics, University of 
California, San Francisco. Telephone interview, 11 August 1994. 
David Sabatini, Professor and Chair of Department of Cell Biology, New York University 
Medical School. Interview at Rockefeller University, 28 March 2001. 
Darrell Salk, Biomedical Scientist. Interview in Seattle, WA, 18 September 1996. 
Interviews in San Diego, 11 April 2000, 4 June 2001. 
Fred Sanger, Emeritus Staff, Laboratory for Molecular Biology, Cambridge, UK. Interview 
at Emmanuel College, University of Cambridge, 7 June 1999. 
Rudi Schmidt, Professor Emeritus of Medicine, former Dean of University of California 
Medical School, San Francisco. Interview in his office, 10 August 1994. 
David Schubert, Professor, Salk Institute of Biological Studies. Interview in his office, 20 
May 2000. 
John Searle, Professor of Biological Philosophy, University of California, Berkeley. 
Interview at Neurosciences Institute, 17 March 1996. 
Fred Seitz, President Emeritus of Rockefeller University. Former President, National 
Academy of Sciences and former Professor of Physics, University of Illinois at 
Urbana-Champaign. Interviews in his office in New York, 15 April 1995, 24 
February 2000, 4 May 2001. 
Maxime Seligman, former director of Unité d’Immunologie et immunopathologie. 
Interview in his office at Hôpital Saint-Louis in English, 21 April 2000 and 30 May 
2000. 
Irving Shain, former Vice Chancellor and Chancellor, University of Wisconsin (Madison), 
and former Provost, University of Washington (Seattle). Telephone interview, 24 
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Steven Shapin, Professor of Sociology of Science, University of California, San Diego. 
Interview in his home, 11 March 1996. Second interview, UCSD Faculty Club, 6 
February 1998. 
Lucy Shapiro, Professor and Chair, Department of Developmental Biology, Stanford 
University School of Medicine. Numerous Interviews, Rockefeller Foundation 
Study Center, Bellagio, Italy, May and June 1996. 
Philip Sharp, Chair and Professor of Biology, and former Director of Center for Cancer 
Research, Massachusetts Institute of Technology. Interview in his office, 3 May 
1995. 
Fritz Sharpf, Director, Max-Planck-Institut für Gesellschaftsforschung (Cologne), Konstanz 
University (Germany), 23 November 1994. 
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Philip Siekevitz, Professor Emeritus of Rockefeller University. Interview in his office, 11 
February 2000. 
John Simpson, Dean of the College of Arts and Sciences, University of Washington 
(Seattle). Telephone interview 5 September 1996, interview in his office 19 
September 1996. 
Piotr Slonimski, former Director, Laboratoire de Génétique physiologique, Gif-sur-Yvette, 
France. Interview in English in his office 15 June 2000. 
Henry Small, Editor, The Scientist. Interview in his office at the Institute of Scientific 
Information (Philadelphia), 31 August 1993. 
Hamilton O. Smith, Professor, Department of Molecular Biology and Genetics, Johns 
Hopkins University, Baltimore. Interview in his office, 21 July 1997. 
Lloyd (Holly) Smith, Professor Emeritus of Medicine, University of California, San 
Francisco. Interview in his office, 10 August 1994, telephone interview, 17 
February 1995. 
Michael Smith, former Director of Biotechnology Laboratory and Professor, University of 
British Columbia (Vancouver). Interview in his office, 5 February 1998. 
Oliver Smithies, Professor of Molecular Genetics and Pathology, University of North 
Carolina (Chapel Hill). Former President of Genetics Society of America. Interview 
in his office in Chapel Hill, 30 March 1996. 
Solomon Snyder, Professor and Director of Neuroscience, Johns Hopkins University. 
Interview in his office, 18 July 1997. 
David Sonneborn, Professor of Zoology, University of Wisconsin. Interview in his office, 
18 December 1997. Second interview by telephone, 23 December 1997. 
Aage Sorenson, Professor of Sociology, Harvard University. Interview at Harvard, 29 April 
1995. 
David Soskice, Director of Science Unit, Wissenschaftszentrum Berlin. Multiple interviews 
at the Wissenschaftszentrum Berlin, April–July 1996, June 1998. 
Gunter Stent, Professor of Molecular and Cell Biology, University of California, Berkeley. 
First interview at his home in Berkeley, California, 11 August 1994; second 
interview, Klosters, Switzerland, 16 January 1995; third interview, Cold Spring 
Harbor Laboratory, New York, 24 August 1995. 
Charles Stevens, Professor, Salk Institute. Interview in his office, 13 December 2000. 
Wolfgang Streeck, Director of Max-Planck-Institut für Gesellschaftsforschung. Interview at 
his home, Cologne, Germany, 7 July 1996. 
Sidney Strickland, Professor and Dean of Graduate Studies, Rockefeller University. 
Interview in his office, 2 April 2001. 
Horst Sund, Professor of Biology and Biochemistry, Konstanz University (Germany). 
Interview 6 December 1994. 
E.M. (Tilli) Tansey, Medical Historian, Wellcome Institute for the History of Medicine. 
Interview in her office, London, 3 May 1997. 
David Tarin, Director, Cancer Center, University of California, San Diego. Interviews in 
his office at UCSD, 22 June, 3 July 2001. 
Louise Taylor, Special Assistant to the Vice Chancellor, University of California, Berkeley. 
Interview in her office, 5 January 1995. 
Howard Temin, Professor in McArdle Cancer Laboratory, University of Wisconsin 
(Madison). Interview at McArdle Cancer Laboratory, 26 November 1993. 
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Esther Thelan, Professor of Psychology, Indiana University. Interview at Neurosciences 
Institute, 7 January 1998. Second interview, 28 January 1998. 
John Thoday, Emeritus Professor of Genetics, University of Cambridge. Interview at 
Emmanuel College, 11 June 1999. 
George Thorn, Levine Professor Emeritus, Harvard Medical School, and former Physician-
in-chief, Peter Brent Brigham Hospital. Interview in his home, Cambridge, MA, 25 
April 1995. 
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